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CHAPTER 1 
 
INTRODUCTION AND BACKGROUND 
 
Importance of Molecular Interactions: 
 Proteins are the molecular machines that carry out the basic biological functions 
in cells and are therefore a major research focus for biologists, chemists, and 
biochemists.1-6  In order to make novel advances in the medical field, it is necessary to 
identify target proteins involved in disease pathogenesis and to determine how these 
proteins interact with other molecules.7  However, binding to proteins can be a complex 
process with multiple aspects to consider, including the mechanism of the binding 
process, the structural basis of the binding, and the functional outcomes.  Factors that 
may complicate interaction studies include multi-step binding, influences from 
post-translational modifications, and sensitivity to the physical and chemical 
environment.  Specifically, changes in environmental factors such as pH, temperature, 
and ionic strength may significantly reduce or completely inhibit binding to proteins.  
Monitoring of binding interactions can be impacted by the stoichiometric ratio of protein 
to ligand, as well as the binding affinity.  Binding studies may also be complicated when 
the protein of interest must first be produced via expression in cells, an often difficult and 
time-consuming process that may produce only a miniscule amount of the protein for 
analysis or screening.  The development of biosensing tools that can accommodate and 
overcome these challenges is critical to the study of molecular interactions.  The work 
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presented in this thesis will focus on the detection of interactions and the measurement of 
the strength of these interactions through the calculation of the dissociation constant (KD).   
 
Methods to Study Molecular Interactions: 
 A number of methods are currently available to monitor binding of ligands to 
proteins, including fluorescence spectroscopy, isothermal titration calorimetry (ITC), 
nuclear magnetic resonance (NMR) spectroscopy, surface plasmon resonance (SPR), 
quartz crystal microbalance (QCM), analytical ultracentrifugation (AUC) and 
interferometry.  Although each is effective for specific applications, these methods also 
possess certain limitations.  Several approaches require a label of some type (e.g. 
fluorescent); some involve complicated surface chemistry (e.g. SPR, QCM), while others 
have low sensitivity and require large sample quantities (e.g., ITC, NMR).  Therefore, 
there is a great need for an efficient detection method that will allow the experiments to 
be performed in small volumes, in free solution, and label-free.  Also, having a single 
approach to the study of a binding system allows for better comparisons between 
measurements. 
 Fluorescence spectroscopy measures the light emitted from a molecule upon 
excitation by a light source.  Fluorescence is a well-established technique used to 
measure binding with very high sensitivity, allowing for the detection of a single 
molecule.8-10  However, fluorescence is often expensive to implement and can only be 
used in systems that are naturally fluorescent (very few) or that have been chemically 
modified with a fluorescent tag.  Furthermore, the addition of a label can greatly affect 
affinity or binding due to an alteration in the protein structure.1   
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 ITC takes advantage of the fact that heat is a universal signal that will always be 
absorbed or produced when compounds interact.  ITC is performed by monitoring the 
heat change for a series of small injections of ligand.  Many values of interest, such as 
ΔG, ΔH, and ΔS, as well as KD, can be extracted from ITC experiments.  However, 
despite the advantage of being able to calculate these constants, the disadvantages of ITC 
are that the assay typically requires long analysis times and significantly more material 
than other methods due to the large sample volumes and the high concentrations 
required.11-14  Large sample quantities are particularly problematic when there is a limited 
amount of the protein available to perform the study. 
 NMR is another tool that has been widely used for the determination of 
dissociation constants, based either on the changes in the chemical shifts, the relaxation 
time measurements, or the diffusion measurements.15-20  A major benefit of NMR is the 
ability to determine structural information about the binding site, given that the three-
dimensional structure of the protein of interest and the NMR assignments of the protein 
backbone are known.21  However the major limitation of NMR methodologies is low 
sensitivity, which results in the need for large amounts of sample.  This results in NMR 
being best suited to studying mid to low affinity ligands.21  Also, chemical shift changes 
are difficult to interpret because they are affected by many factors.15-22   
 SPR has also become a common technique for label-free monitoring of protein 
binding in small volumes.23-28  SPR measures the localized change in the refractive index 
(RI) near the surface in order to detect binding29-32 and has been used in a multiplex 
format.33  SPR has the advantage of being able to determine forward and reverse reaction 
rates of the binding in order to calculate the dissociation constant.  However, any 
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refractive index change between different solutions must be taken into account when 
using this technique.  Also, SPR is a heterogeneous method that requires complicated 
surface chemistry and expensive gold-plated slides.30,31,33  The attachment of a molecule 
to a surface can also change the protein structure which can affect the binding23 and/or 
alter the affinity of the interaction,13,27,28,34,35 especially if the molecule must be mutated 
in order to make the attachment possible.36  Furthermore, the surface loading of the chip 
is critical to protein binding determinations as different methods of attachment can cause 
variations in the KD values calculated.  Finally, the SPR measurements are mass 
sensitive, which makes it difficult to monitor the binding of a small ligand to a large 
protein without immobilizing the ligand.11,27,28,37,38 
 QCM is comprised of a small crystal disc that is positioned between two 
electrodes.  When a voltage is applied to the electrodes, the crystal is strained causing it 
to resonate at a unique frequency.  The resonance frequency of the crystal is altered when 
there is a change in mass at the surface of the crystal.  QCM can therefore be a very 
sensitive technique to study molecular interactions by immobilizing a receptor to the 
surface of the crystal; measuring the change in the resonance frequency of the crystal as 
the ligand binds.39-41  Since the frequency of the crystal resonator is sensitive to any 
change at the surface, non-specific binding can be problematic and must be carefully 
accounted for.  It is also necessary to thoroughly calibrate the system with the solutions to 
adjust for any affect the liquid may have on the resonance frequency.42  QCM is also 
limited to a surface immobilized format, which can change the conformation of proteins 
and alter the measured affinities.23,36  
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 AUC monitors the sedimentation of molecules in a centrifugal field in order to 
measure the binding of molecules by separating the bound and unbound molecules based 
on their size and shape.43-45  AUC can measure interactions in free solution with modest 
requirements for sample quantity, but instrumentation can be difficult, requiring optical 
measurements to be taken while the sample is spinning at high speeds.43,46  Additionally, 
common stabilizers, such as sugars, can hinder detection and must be carefully taken into 
account.47 
 
Interferometric Methods: 
 When two or more light waves are superimposed, an interference pattern is 
created.  By studying these patterns, the properties of the light waves and the material 
that they have been in contact with can be explored.  This field, known as interferometry, 
has led to the development of some of the most sensitive optical techniques available and 
has been implemented for various applications, including astronomy, metrology, 
oceanography, seismology, and biological sciences.  
 Interferometry has also been applied to biological sciences as a tool to monitor 
and quantify molecular interactions.48  Interferometry also offers the dual advantage of 
being a highly sensitive technique that does not require the use of expensive molecular 
labels.  Therefore, molecular interactions may be characterized with both binding 
partners in their native states, eliciting quantitative, meaningful (i.e. unperturbed by 
labeling) affinity data in a cost-effective format.  Here we describe several different types 
of interferometers which have been successfully utilized to study molecular interactions. 
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Mach-Zehnder Interferometer: 
 The Mach-Zehnder interferometer (MZI) utilizes a waveguiding method to 
monitor the difference in refractive index (RI) between the sample and the reference arm 
of the waveguide (Figure 1.1).  A laser illuminates a single-mode waveguide which is 
then split into a sample and reference arm.  The reference arm is coated with a thin 
cladding layer, while the sample arm has a window to allow the evanescent field to 
interact with the sample.  The sensor and reference arms are then recombined, leading to 
beam interference.  Any change in the sample’s refractive index produces a phase shift in 
the sensor arm beam, which in turn results in a change in the output intensity when the 
two beams are recombined.  Binding events are thereby measurable using photodetection.  
Intrinsically, the evanescent sensing approach of the MZI instrumental configuration 
requires a single polarization and single-mode illumination to prevent interference from 
cross-polarization and multimodal effects.  The sensitivity of the MZI is typically 
correlated with the length of the sensing window, which makes it difficult to measure low 
concentrations of analytes without using large amounts of sample.   
 The MZI was first used for biosensing in 1993 and has since been utilized in a 
broad range of applications.48-52  In 1997, Brosinger et al., demonstrated the ability to 
resolve a refractive index change of 2 × 10−5 refractive index units (RIU) with their early 
MZI configuration.49  Initial experiments to test the biosensing ability of the instrument 
were also reported, demonstrating that MZI can detect fetal calf serum binding 
nonspecifically to the sensor surface.49  More recently, Prieto et al. used a Mach-Zehnder 
interferometer total internal reflection (MZI-TIR) configuration to achieve a minimum 
refractive index change of 7 × 10−6 at the sensor surface.  The utility of the instrument 
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was demonstrated by detecting the interaction between a covalently immobilized 
pesticide and its antibody in PBST (phosphate buffered saline Tween).50  The same group 
also constructed an MZI based on a rib anti-resonant reflecting optical waveguide 
(ARROW).  The use of ARROW structures instead of conventional TIR waveguides 
allows for larger core and rib dimensions, making the instrument more compatible with 
mass-production, as well as lowering insertion losses.  However, these advantages are 
accompanied by a loss in sensitivity as the minimum detectable refractive index change 
for the MZI-ARROW was found to be 2 × 10−5.51   
 
Young Interferometer: 
 Another waveguiding interferometer is the Young interferometer (YI).  The YI 
configuration includes a single-mode laser illuminating a single-mode waveguide, which 
is then split into a sample and reference arm, as in the Mach-Zehnder interferometer 
Light Source
Reference
Channel
Camera
Interaction Channel
 
Figure 1.1:  Block diagram of a Mach-Zehnder interferometer (MZI). 
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(Figure 1.2).  However, instead of the interference being created when the waveguides 
recombine as in the MZI, in a YI the optical output of the waveguides interact in free 
space to create the interference fringes, which are displayed onto a CCD camera.   
 The YI was first used to measure molecular interactions in 199448 and has been 
widely published on thereafter.53-55  In 2003, Ymeti et al. showed that their multi-channel 
YI configuration can measure four different analyte concentrations simultaneously, 
achieving a refractive index resolution of 8.5 × 10−8 RIU.53  In 2006, Hradetzky et al. 
reported a refractive index detection limit of 0.9 × 10−6 for their single-cell YI, and 
detected the hybridization of 21-mer DNA with immobilized receptor DNA at the 
biosensor surface.54  These finding suggest the detection limit of this DNA-DNA binding 
interaction to be in the picomolar range. 
 
 
Cylindrical Lens
Light Source
Interaction Channel
Reference Channel
Camera
 
Figure 1.2:  Block diagram of a Young interferometer (YI). 
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Hartman Interferometer: 
 The Hartman interferometer (HI) is also a waveguiding technique; however, in 
contrast with the MZI and YI, this approach utilizes a planar waveguide that is patterned 
with lines of immobilized molecules.  Light is directed into the waveguide through a 
grating to create a single broad beam.  The light then passes through parallel sensing 
regions which are coated with different receptors to create distinct binding and control 
regions.  The light then travels though integrated optics that combine the light from 
neighboring regions to create interference.  The interference signals then pass through 
another grating and to the detector.  The phase shift of the interference patterns is 
measured to detect refractive index changes. 
 In 1997, Schneider et al. demonstrated the broad applications of the HI as a real-
time detector of nucleic acid, protein, and pathogen analytes.  Experiments were 
performed by immobilizing the receptor (anti-hCG antibody) to the sensor surface, 
allowing for real-time detection of human chorionic gonadotropin (hCG) with a direct 
detection limit of 2 ng/mL in phosphate buffered saline (PBS).  DNA hybridization 
 
 
Light Source
Input GratingReceptorsOutput Grating
Detector
Optical Elements
 
Figure 1.3:  Block diagram of a Hartman interferometer (HI). 
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experiments detected a four-base mismatch in 50% formamide hybridization buffer, and a 
nucleic acid detection capability of 1011 copies per mL was achieved.56  In early 2000, the 
same group expanded on these applications, demonstrating the ability of their 
configuration to detect hCG in human serum at clinically relevant levels of 0.1 ng/mL.  
Extensive studies of the nonspecific binding associated with serum samples were also 
performed, which concluded that the HI can overcome this particular setback using a 
reference region and controlled surface chemistry.57  Later that year, Schneider et al. took 
their studies a step further by detecting hCG in whole blood; despite significantly higher 
background levels than buffer or serum systems, a clinically relevant detection limit of 
0.5 ng/mL hCG was achieved.58 
 
Diffraction Optics: 
 Diffraction-based sensing employs a similar technique of immobilizing the probe 
molecules into a pattern that will diffract the incoming laser light to create an interference 
pattern (Figure 1.4).  This pattern has been shown to change as sample is introduced and 
binding occurs on the stripes of capture species, resulting in a change in the height and 
refractive index of the diffraction grating.  The intensity of the refractive spots is 
measured using a photodectector, allowing any changes within the sample to be 
measured.  While many applications of diffraction optics offer enhanced performance 
when used in conjunction with labeling strategies, the following examples focus 
primarily on label-free applications of the technique.  
 Early studies by St. John et al. demonstrated that diffraction optics can be used to 
detect whole bacteria cells captured using an antibody grating stamped on a silicon 
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surface.59  Goh et al. demonstrated the ability of diffraction optics to measure two 
different binding interactions simultaneously without the use of labels.  To achieve this, 
receptor molecules mouse IgG and rabbit IgG were immobilized in two different patterns 
via PDMS stamping on the same 2D surface.  Anti-mouse IgG and anti-rabbit IgG were 
then introduced into the cell sequentially and the binding observed for each pattern 
indicated specific binding of the target analyte exclusively to its receptor antibody.  These 
findings carry implications for diagnostic applications involving multiple markers and/or 
competition assays.60  Currently, Axela Biosensors offers a commercialized diffraction-
based sensor known as the dotLab™ System which enables multiplexing of 
immunoassays over a broad dynamic range.  They demonstrated the ability to 
simultaneously measure binding of two similar sets of antibody/analyte pairs with 
concentrations which differed by 6 orders of magnitude; however, labeling strategies 
were implemented to measure the analyte of lower concentration.61  Savran et al. has 
used diffraction optics coupled with a magnetic bead labeling system to quantify 
Light Source
Patterned 
Substrate
Diffraction 
Image
 
Figure 1.4:  Block diagram of diffraction optics. 
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biomarkers S-adenosyl homocysteine (in solution) and folate receptor (in serum) with 
sensitivities of 24.5 pg/mL and 20 pg/mL, respectively.62,63 
 
Dual Polarization: 
 The dual polarization interferometer (DPI) is another waveguide method for 
studying molecular interactions.  This technique utilizes two waveguides, a sample and 
reference waveguide, which are stacked together, so they may be illuminated by a single 
laser with the resultant light exiting the waveguides form an interference pattern in the far 
field (Figure 1.5).  In contrast with other waveguide sensors, the polarization of the laser 
in the DPI is alternated so that two polarization modes of the waveguides are excited in 
succession in order to modulate the signal and increase sensitivity.  Using the information 
from the measurements of both polarization states, the refractive index and the thickness 
of the adsorbed protein layer can be calculated. 
 Swann et al. measured the binding and surface loading of streptavidin to the 
biotin-functionalized surface of their DPI to monitor nonspecific binding, thickness, and 
 
 
Reference Waveguide
Sensing Waveguide
Light Source
Biological Layer
Output of the two 
waveguides creates 
farfield interference 
fringes
 
Figure 1.5:  Block diagram of a dual polarization interferometer (DPI). 
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density changes of protein layers as well as other structural aspects of the streptavidin-
biotin system.64  In 2006, Lin et al. used DPI to derive dissociation constants (KD) for 
homopolyvalent pentameric C-reactive protein (CRP) with monoclonal anti-CRP IgG; 
these values were in close agreement with those previously derived using enzyme-linked 
immunosorbent assays (ELISA).65  That same year, Ricard-Blum et al. measured the 
interaction of immobilized heparin with heparin binding protein HepV.  Exploring the 
stochiometric and kinetic parameters of this binding system using DPI lent insight into 
collagen V interaction with proteoglycans in tissues, a process which affects collagen 
fibril formation.66  Wang et al. utilized DPI to measure the structural changes of 
electrostatically immobilized DNA upon binding to small molecules ethidium bromide 
and spermine in real time.  Changes in mass, thickness, and refractive index of the DNA 
sample layer (consisting of either native or denatured DNA) were monitored upon small 
molecule binding.  These studies harnessed the ability of DPI to measure structure and 
kinetics simultaneously and the flexibility of the technology to interrogate binding 
interactions over a large molecular size range.67  Farfield Sensors, Ltd has been 
commercializing DPI-based biosensing systems since 2000 with the introduction of the 
AnaLight® 250, and has most recently released the AnaLight® 4D which enables the 
measurement of structural changes within lipid bilayers.68,69 
 
Porous Si Sensors: 
 Porous silicon sensors have been developed using the principles of the Fabry-
Perot interferometer on thin films of porous silicon etched in a silicon substrate (Figure 
1.6).  The porous Si film acts as the interferometer, creating fringes from reflections off 
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the top and bottom of the pores.  As demonstrated by Sailor, et al., this technique can 
overcome typical penetration depth limitations because the entire volume of the sample 
within the film is utilized for the measurement.70,71  Limited penetration depth, or the 
inability to measure interactions which occur above the sensor surface, is a significant 
shortcoming present in other surface-based techniques.  
 Lin, et al. reported the ability of a porous silicon-based optical interferometric 
bionsensor to detect the binding of small molecules, DNA oligomers, and proteins with 
unprecedented sensitivity (pico- and femtomolar concentrations).70  Dancil et al. studied 
protein A and IgG binding via porous silicon biosensing.  This report highlighted the 
reversibility and stability of the system, as well as the ability to render the sensor 
insensitive to nonspecific binding.71   Li et al. demonstrated that porous silicon can serve 
Light Source Detector
 
Figure 1.6:  Block diagram of a porous silicon sensor. 
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as a template for the construction of complex optical structures comprising of organic 
polymers or biopolymers in biosensor applications.  These more recent findings are of 
particular interest to drug delivery applications.72  
 
BioCD: 
 The biological compact disk (BioCD) utilizes patterns of immobilized capture 
proteins on a disk with a mirrored surface to create periodic reflective interference 
spectra which are measurably altered by binding.73,74  The interference signal is 
interrogated before and after the disk has been incubated with the sample, and the 
difference is correlated to the amount of binding that has occurred.  Unfortunately, 
because the BioCD discretely measures the relative difference in the reflectance patterns 
of surface immobilized proteins before and after binding, the tool is not readily applicable 
for real-time monitoring, rendering kinetics studies problematic.   
 Detection limits as low as 105 molecules has been achieved using the BioCD, 
which was employed to measure specific binding between anti-mouse IgG and mouse 
IgG using rabbit IgG as a control.73,74  In an expanded effort, it was shown that binding 
measurements are concentration-dependent, illustrating the potential of the technique for 
quantitative analyses.75  Wang et al. expanded applications of the technique further by 
employing the BioCD to perform multiplexed prostate specific antigen (PSA) detection 
in human serum.76  
 
Other Reflective Interferometric Platforms: 
 Recently, the principles of reflectance interferometry used in porous silicon and 
BioCD methods have been applied to other biosensor variations with increased 
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multiplexing abilities.  In particular, Ozkumer et al. have introduced a multiplex platform 
known as the spectral reflectance imaging biosensor (SRIB) designed for high throughput 
use.  SRIB is based on the optical phase difference rendered by the binding of biological 
species to probes on a transparent layered surface.  This technique enables the collection 
of reflectance spectra for hundreds of spots on the array simultaneously.77,78  Gauglitz et 
al. have used reflective interferometric spectroscopy (RIfS), a similar platform based on 
multiple white light reflections at thin transduction layers, to characterize biomolecule 
interactions in a multiplexed, high throughput format by attaching 96- and 384-well 
plates to the transducer slide.79  The applications of this RIfS platform include use a 
screening tool for thrombin inhibitors and antibodies against triazine libraries.79,80  
 
Backscattering Interferometry: 
 A new technique, backscattering interferometry (BSI), was originally used to 
measure small refractive index changes in fused-silica capillaries81 and has been 
developed in multiple configurations and for a wide array of applications, including a 
highly sensitive universal solute detector in capillary electrophoresis,82-84 a non-invasive 
nanoliter temperature probe,84,85 a highly accurate flow sensor,86,87 as well as an ultra-
sensitive method for the detection of proteins.88-90  BSI has more recently been employed 
to study molecular interactions in a label-free method91 and has proven to be a versatile 
sensing technique; BSI can investigate binding events in both a surface immobilized 
scheme and in free solution.  This ability to measure interactions in a free-solution format 
makes BSI unique among interferometric techniques.  The free-solution advantage not 
only eliminates the time and monetary costs related to immobilization strategies, but also 
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allows binding partners to be monitored entirely in their native state.  As BSI is dually 
amenable to free-solution and surface-immobilized formats, any contribution of 
immobilization to binding perturbation may be measured directly.  Perhaps surprisingly 
in light of the platform’s unmatched versatility is that BSI maintains an extremely simple 
optical train, requiring only a collimated coherent light source, a capillary or microfluidic 
chip (hemispherical or rectangular), and a detector.   
 In the latest configuration of BSI, a microfluidic chip molded in 
polydimethylsulfoxide (PDMS) or etched in glass is employed.  BSI utilizes a red 
helium-neon (HeNe) laser (λ = 632.8 nm) to illuminate the microfluidic channel in a 
simple optical train (Figure 1.7).  Specifically, the laser is coupled to a collimating lens 
through a single-mode fiber, producing a 100 μm diameter beam and yielding probe 
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Figure 1.7:  Block diagram of Backscattering Interferometry (BSI). 
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volumes in the 300 picoliter range.  Subsequently, when the laser beam impinges the 
channel and interacts with the fluid contained in the channel, a set of high contrast 
interference fringes is produced and monitored in direct backscatter region at relatively 
shallow angles.  The spatial position of these fringes depends upon the refractive index 
(RI) of the fluid within the channel (Figure 1.8).  The change in fringe position is 
monitored using a CCD array in combination with Fourier analysis,92 enabling the 
quantification of this positional shift as a change in spatial phase, calculated in the 
Fourier domain. 
 Originally BSI facilitated interaction assays in the heterogeneous mode, or 
utilized the immobilization of one binding partner onto the surface of a microfluidic chip 
molded in PDMS.90,93  In early experiments, streptavadin was immobilized onto the 
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Figure 1.8:  A. Line profile of the fringes produced with a shift illustrated.  B. Fourier analysis of 
the two fringe patterns, showing the same frequency.  C. Phase versus time plot illustrating the 
signal change observed for the fringe shift shown in A. 
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channel surface and the fringe pattern was measured before and after introducing biotin 
into the channel.  A good correlation was found between the BSI molecular interaction 
signal and fluorescence signal reported in a similar experiment.  Next, a biotinylated 
protein-A (PA) surface allowed the monitoring of reversible IgG-PA interactions with 
femtomole detection limits.90  New surface chemistry enabled a two-fold improvement on 
detection limits of the protein A-IgG interaction without the use of a fluorescent label, 
and also allowed monitoring of the hybridization of complimentary strain of DNA at 
concentrations ranging from 5nM to 500 mM to a 30-mer of mActin.  Assuming 100% 
surface coverage, the 3σ limit of quantification was found to be 36 attamoles of DNA in 
the 500 pL detection volume.  Further experiments showed that a 3 base pair mismatch 
could be detected, evidenced by a marked decrease in binding signal from that of the 
original complimentary strand – only 7 % of the signal generated by the binding of the 
complimentary strands was observed for the mismatched strand.93 
 The most novel aspect of BSI is that it can be used to measure free-solution 
molecular interactions.  Using a channel with a serpentine mixer and a restriction to mix 
the two interacting species on-chip, a stop-flow experiment can be performed label-free 
and in free solution to elicit real-time kinetic data.  Solutions may also be pre-mixed off 
chip, enabling the determination of kinetic information using an end-point format.91  
Using these methods, systems reported were Protein A (PA) which binds with high 
affinity to the FC region of several immunoglobulin G (IgG) species, including human 
and rabbit; calmodulin (CaM), the ubiquitous calcium-binding protein that can bind to 
and regulate a multitude of different protein targets; and the interaction between IL-2 and 
a monoclonal antibody, in this case in buffer and in cell-free media.  Recent 
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advancements of BSI have shown that molecular interaction assays can be performed 
utilizing exceedingly small amounts of sample at physiologically relevant concentrations, 
without the use of labels or surface immobilization, and in complex matrices.  For 
example, the entire CaM study (i.e., CaM-Ca2+, CaM-TFP, CaM-M13 peptide, and CaM-
calcineurin) required the consumption of only about 200 picomoles or 3 mg of CaM, and 
each binding event only required one minute for analysis.91 
 The broad range of unique applications that BSI is capable of will be reported in 
this thesis.  The limits of BSI for the use in binding affinity determinations will be 
expanded to the pM range (Chapter II) through the study of the interaction between 
interleukin-2 (IL-2) and its monoclonal antibody (IL-Ab).  IL-2 is a well-studied 
protein94,95 that is secreted by activated T-cells and is involved in the regulation of the 
immune response.  The interaction between IL-2 and IL-Ab has a high binding affinity 
(10 – 60 pM),96 making it a difficult pair to study with most traditional methods. 
 Another system of particular interest is protein – carbohydrate binding (Chapter 
III), which is involved in many cellular recognition pathways such as immune response, 
cell agglutination and aggregation, as well as the initiation of numerous diseases.97-100  
Due to this fact, carbohydrates have become a target for the development of inhibitors 
that would be applicable to a broad variety of diseases.100,101  The primary difficulty in 
studying the protein-carbohydrate system is that there is significant difference in the size 
of the binding pair. 
 Another prime area of investigation is the implementation of BSI for use in 
disease detection (Chapter IV).  Current methods for the detection of many diseases, 
include cell cultures, ELISA (enzyme-linked immunosorbent assays), nucleic acid 
21 
amplification tests (PCR and LCR), and direct immunofluorescence (DIF).  These 
methods often require the patient samples to be sent off to a lab for analysis, which may 
take several days.  This procedure causes a delay in treatment and, in some instances, the 
patient does not even return for treatment.  The lack of a rapid test often results in the 
empirical use of antibiotics, which may be prescribed to a patient in error.  If a method 
were available to accurately diagnose a disease in the doctor’s office instead of having to 
send it off to a lab, the correct treatment could begin immediately.  To test the 
applicability of BSI for disease diagnosis and therapy monitoring, syphilis will be used as 
an example through a collaboration with the Sexually Transmitted Disease (STD) 
division of the Centers for Disease Control and Prevention (CDC). 
 BSI is also uniquely applicable to the study of membrane bound proteins (Chapter 
V).  Membrane-associated proteins are integral components of many cellular processes 
and disease pathogeneses.  Direct and quantitative observations of ligand-protein 
interactions are notoriously difficult to perform due to the associated membrane.  Though 
assays exist to examine this class of molecular interactions, targets of interest must 
typically undergo covalent modification and removal from the native membrane 
environment prior to observation.  Here BSI will be used to observe ligand-receptor 
binding events in a solution-based, native membrane environment.  
 Various other applications of BSI are currently being explored (Chapter VI), 
including antibody interactions for an array of small molecules and encapsulated RNA 
aptamer interactions. 
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CHAPTER II 
 
PROBING HIGH-AFFINITY INTERACTIONS WITH  
BACK-SCATTERING INTERFEROMETRY 
 
Background and Significance: 
 Molecular interactions, such as protein-protein binding or protein-small molecule 
binding, are fundamental to basic cellular function.  Valuable insight to these functions is 
provided by the ability to study these interactions and to determine the affinity and rate.  
Such investigations provide the foundation for many diagnostic techniques and critically 
aid in the development of therapeutics.  For many of these interaction measurements to 
be performed, very low concentrations must be utilized, often necessitating the 
attachment of labels (such as fluorescent tags) to at least one of the binding partners.  
Techniques designed to avoid labeling have traditionally been accompanied by other 
disadvantages; for example, label-free measurements have been performed using 
calorimetric methods, such as isothermal titration calorimetry (ITC) are carried out in 
free solution and have become relatively well accepted.102-104  However, there are 
limitations to calorimetry, including large sample volumes, relatively low sensitivity, and 
low throughput.  The enthalpic array has been developed to overcome some of the 
limitations of calorimetry, allowing measurements to be performed in 500 nL of sample 
and in a high-throughput format.105  Nevertheless, the method is still limited by its 
sensitivity, with concentration detection limits around 50 µM,105 thus constraining the 
measurable range of binding affinities.  Label-free techniques that have the necessary 
sensitivity however often rely on surface immobilization, which can be expensive and 
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time consuming as well as having reduced activity over time.23  In addition, immobilizing 
one of the binding pair to a surface can alter how the molecules interact.106 
 Backscattering interferometry (BSI) has previously been used with surface 
immobilization methods90,93 and has recently been applied to free solution molecular 
interaction assays.91  Here we show that BSI has the sensitivity necessary to probe high 
affinity (pM) binding events, expanding the molecular interaction dynamic range of the 
instrument to six decades.91  To test the limits of BSI for use in binding affinity 
determinations, the binding between interleukin-2 (IL-2) and its antibody (IL-Ab) will be 
quantified in free-solution and label-free.  IL-2 is a well-characterized protein that is 
secreted by activated T-cells and is involved in the regulation of the immune response, 
directing the proliferation and differentiation of immune cells.94,95  The interaction 
between IL-2 and IL-Ab have been shown to bind with high affinity (10 – 60 pM),96 
making this pair difficult to study with most traditional methods. 
  
IL-2 Calibration: 
 A calibration curve of the protein in solution (4 mM HCl with 0.1% FBS) was 
first performed using a concentration range from 10 – 100 pM.  In these studies, a 
rectangular microfluidic channel (90 μm × 50 μm) molded in poly(dimethyl)siloxane 
(PDMS) was used, representing a probe volume of 450 pL.  These were prepared 
utilizing standard photolithography and replica molding techniques.107,108  Approximately 
4 μL of solution was introduced into the inlet well and was subsequently loaded into the 
channel by applying a vacuum to the waste outlet.  After allowing the solution to 
equilibrate to temperature and pressure, the phase shift was recorded using a program 
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previously developed in our group.92  The experiment was repeated in triplicate.  The 
resulting calibration curve for IL-2 proved, as expected, to be linear (R2 = 0.985) and 
produced a 3σ detection limit of 40.2 pM (Figure 2.1), equivalent to 10,900 molecules or 
278 ag of protein within the probe volume. 
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Figure 2.1:  Calibration curve of IL-2, error bars represent the three run standard deviation. 
 
 
Free Solution Binding: 
 A chip with a serpentine mixer molded in PDMS was used for the binding 
experiments (Figure 2.2).  The antibody solution was introduced into one inlet well and 
the IL-2 solution was introduced into the other inlet well.  A vacuum was applied to the 
waste outlet to draw the samples through the serpentine, mixing the samples on the chip.  
The vacuum was then removed, stopping the flow and the binding between IL-2 and 
IL-Ab was monitored.  An example of a real-time trace of the signal before and after the 
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flow is stopped in shown in Figure 2.3.  Here the time scale is arbitrarily set to zero at the 
time that the vacuum is released and the flow is stopped.  Before this point (at negative 
times), there are freshly mixed reactants that have not yet bound flowing in the channel.  
When performing the binding assay, the concentration of IL-Ab was held constant at 2 
nM (in PBS, pH 7.4), while the concentration of IL-2 was varied from 10 – 100 pM (in 4 
mM HCl with 0.1% FBS).  The reaction was monitored for three minutes, at which time 
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Figure 2.3:  Time-dependent BSI signal before (t < 0) and after (t > 0) flow of reactants is 
stopped by removing vacuum nozzle from the chip outlet port.  Total time shown is ½ second 
from a reaction lasting several seconds under these conditions. 
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Figure 2.2:  Image of the serpentine mixer chip utilized in the free-solution binding experiments.
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the signal remained relatively stable, indicating that the reaction was complete (Figure 
2.4).  Due to the different solvents used for the protein and the antibody, three separate 
control runs were performed.  The solvents of each molecule were mixed first (black), 
followed by the highest concentration of IL-2 mixed with the antibody buffer (red), and, 
finally, the antibody in the absence of the protein (blue).  There was a slight signal 
produced by all of the blanks, however the change was consistent for all three controls, 
demonstrating that this change is simply the result of the mixing and any environmental 
perturbations.  
 The free-solution binding experiment was then repeated in cell media (RPMI 
1640 with 1% fetal bovine serum (FBS) and 10 µg/mL Cipro) to closer mimic the native 
environment of the interaction.  The IL-Ab concentration was again held constant at 2nM 
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Figure 2.4:  Real-time IL-2 – Ab binding curves with interaction assay performed in free 
solution.  Note: no signal change observed in 3 control experiments (Black: IL-2 buffer mixed 
with Ab buffer, Red: max IL-2 concentration mixed with Ab buffer, and Blue: IL-2 buffer mixed 
with 2nM Ab). 
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and the IL-2 concentration was varyed from 10 – 100 pM.  Similar results were seen for 
the reaction in cell media as were seen in buffer solutions (Figure 2.5).   
 
Data Analysis: 
 The binding reaction between a receptor (R) and a ligand (L) (Equation 1) have 
been shown to have kinetics with first order exponential association.91 
 
R + L RL
kforward
kreverse  (1) 
Therefore the trace of the association between the binding partners was fitted with a one-
phase exponential association (Equation 2) using SigmaPlotTM software. 
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Figure 2.5:  IL-2 – Ab binding curves with interaction assay performed in cell media.  The IL-Ab 
concentration was held constant at 2 nM.  Both the IL-2 and IL-Ab solutions were made utilizing 
RPMI 1640 cell media with 1% FBS and 10 μg/mL Cipro.  A blank [0 M of both IL-2 and IL-Ab, 
(black)], as well as two controls [0 pM IL-2 reacted with 2 nM IL-Ab (blue); 100 pM IL-2 mixed 
on chip with 0 nM IL-Ab (red)] were evaluated. 
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  xkobseyy  1max  (2) 
Here kobs is the observed rate constant of the reaction.  A plot of kobs versus concentration 
can then be generated and fitted with linear regression.  The slope (m) of this line 
corresponds to the kforward and the y-intercept (b) is kreverse, the rate constants in the 
forward and reverse reactions (Equation 1).  
 The KD can then be determined from the ratio of kreverse to kforward (Equation 3). 
 m
b
k
k
forward
reverse DK
 (3) 
This calculation of KD provides a straightforward method of determining the KD of the 
system based on the kinetic data of the binding event.91 
 The KD determination was performed from the binding curves in cell media 
(Figure 2.6) and yielded a value of 25.9 ± 5.2 pM.91  This value falls within the published 
 
 
 
Figure 2.6:  Observed rates determined by exponential fits of kinetic traces for the IL-2 – IL-Ab 
binding assay in cell media. 
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literature values (10 – 60 pM).96  This experiment verifies that BSI can be used to 
quantify binding affinities for a range spanning six orders of magnitude (µM to pM).91 
 
Conclusions: 
 It has been shown the BSI can now be used to measure molecular interactions 
with picomolar binding affinities.  This expands the dynamic range of KD values that BSI 
is capable of measuring to span six orders of magnitude.91  The instrument provides 
excellent sensitivity, being able to monitor picomolar affinity interactions and to detect 
tens of thousands of molecules, while still maintaining a free-solution, label-free format.  
These benefits make BSI unique, enabling previously impossible molecular interactions 
studies.  Perhaps BSI will shift the paradigm when attempting to quantify affinity, 
determine labeling perturbation, or screen for binding. 
 
30 
CHAPTER III 
 
MEASUREMENT OF MONO- AND POLYVALENT CARBOHYDRATE-LECTIN 
BINDING BY BACK-SCATTERING INTERFEROMETRY 
 
Background and Significance: 
 Carbohydrate-protein interactions transmit an immense amount of information 
during intracellular and extracellular processes.97,98,109-113  As a result, functional 
glycomics has taken its place among genomics and proteomics as a vital area of 
investigation for the understanding and treatment of cellular biology and disease.114  A 
fundamental datum in the study of any carbohydrate-protein interaction is the binding 
constant.  Because of the size mismatch in the binding partners and the fact that 
carbohydrates do not usually contain functional groups that induce large changes in 
protein absorbance or fluorescence, quantitative determinations of binding affinities are 
often quite difficult to obtain.  The installation of labels (fluorophores, spin labels, 
crosslinking agents) on the carbohydrate, while necessary in many cases, runs the risk of 
distorting the binding function that is being studied.  The most popular label-free 
technique in recent years has been surface plasmon resonance (SPR),27,28,115-121 with 
quartz crystal microbalance (QCM) technology emerging as a promising alternative at 
lower cost.119,122-124  Both methods require the immobilization of one of the binding 
components on a chip, with the other partner incubated with or flowed over the chip 
surface.  The only method in common use for label-free quantitation of binding constants 
in solution is isothermal titration calorimetry (ITC).125-128  However, ITC is relatively 
insensitive, time-consuming, and often requires large amounts of sample. 
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 Because both SPR and QCM techniques detect changes in mass upon binding, the 
small carbohydrate is usually immobilized and the large protein binding partner presented 
in solution.28,115,121  Several examples of the reverse format (addition of free sugar to 
immobilized lectin) have appeared,37,129-132 but sensitivity and accuracy are generally 
limited.133  One attempt has been made to address this problem for carbohydrates with a 
heavy linker to enhance the mass-sensitive SPR signal upon binding.134  
 Described here is the use of a fundamentally different technique, backscattering 
interferometry (BSI), for the quantitation of binding constants of carbohydrate-lectin 
interactions.  BSI is highly sensitive and can be used on surface-tethered species90,93 or on 
binding events that take place in free solution.91  BSI has been previously described for 
its use in the detection of IgG-protein A interactions and DNA hybridization93 and 
recently reported the quantification of binding affinities over six decades (µM – pM) with  
small molecule-protein, protein-ion, protein-protein, protein-peptide, and antibody-
antigen systems.91  It is shown in this chapter that BSI can now be used to obtain highly 
reproducible binding constants for the interactions of both monovalent and polyvalent 
carbohydrates with lectins that have been immobilized in a very mild manner so as to 
support their native structure and function. 
 
Experimental Procedure: 
 
Surface Immobilization of Lectins: 
 BSI chips were manufactured by Micronit, Inc and were isotropically etched in 
borosilicate glass to give a cross section described by two quarter-circles of 40 µm radius 
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connected by a 10 µm flat region.  A layer of avidin was first immobilized, to which 
biotinylated lectins were attached by simple mixing (Figure 3.1), by the method of 
Matsunaga and coworkers.135  In preparation, the channel surface was cleaned with 10% 
KOH in methanol for 30 minutes, then rinsed with deionized water and dried in air.  The 
channel was then filled with a solution of 3-mercaptopropyl triethoxysilane (1, 2% in 
toluene) for 60 minutes to introduce surface thiol groups, then rinsed again with 
deionized water air dried.  The surface was condensed with a bifunctional linker by 
filling the channel with N-[γ-maleimidobutyryloxy]succinimide ester (2, 1mM in absolute 
ethanol) for 30 minutes.  The channel was again rinsed and air dried.  The surface-
tethered N-hydroxysuccinimide ester groups were used to capture extravidin by soaking 
the channel in a solution of extravidin (1 mg/mL in PBS) overnight, as indicated by 
wash-resistant changes in surface wetting and interferometry.  The channel was 
thoroughly rinsed with PBST (PBS with 0.05% Tween-20) and PBS to remove any 
 
 
 
Figure 3.1:  Functional preparation of immobilized lectins in for BSI measurements. 
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excess avidin.  The activity of the immobilized avidin was independently verified by 
fluorescent labeling of the channels using biotinylated fluorescein (Figure 3.2).136  
 Biotinylated lectins (1 mg/mL) were then introduced to arrive at the fully charged 
channel and soaked for 60 minutes, followed by washing with sodium acetate buffer.  
The use of an extravidin layer was designed to make the system as modular as possible, 
and also to install the binding protein of interest in a less denaturing environment than it 
would experience if tethered directly to the glass surface. 
 For the experiment with different surface coverages, conA was biotinylated by 
mixing it with a 10-fold molar excess of N-hydroxysuccinimidobiotin for one hour at 
room temperature, followed by filtration three times through 10,000 MW cutoff 
 
Figure 3.2:  Microscope images of a representative BSI channel following surface 
functionalization and extravidin attachment, followed by treatment with biotinylated fluorescein, 
and then removal by treatment with concentrated sulfuric acid, which strips all attached material
from the surface so the channels can be re-used. 
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microcentrifuge filtration tubes to remove the excess reagent, rinsing with 50 mM sodium 
acetate buffer containing 1 mM Ca2+ and Mn2+ (pH = 6.8).  
 
Backscattering Interferometry Measurements: 
 BSI has been described in detail previously;90,91 a brief summary of the apparatus 
and method are shown here.  The instrument consists of a red helium-neon (HeNe) laser 
(λ = 632.8 nm) to illuminate the microfluidic channel and a camera for transduction of 
the signal contained in the fringe pattern.  In a simple optical train, the laser is coupled to 
a collimating lens through a single-mode fiber, producing a 100 µm diameter beam and a 
probe volume of approximately 300 picoliters.  When the laser beam impinges the 
channel and interacts with its surface, a set of high-contrast interference fringes is 
produced.  The spatial position of these fringes depends upon the refractive index of the 
fluid within the channel and is monitored in the direct backscatter region.  The change in 
the fringe position is quantified using a CCD array in combination with Fourier analysis 
methodology that allows the positional shift to be interpreted as a change in phase, 
calculated in the Fourier domain.  All data was collected in real-time utilizing an in-house 
program written in LabView™. 
 To perform the binding studies, the lectin was immobilized onto the surface of the 
channel utilizing the scheme outlined above.  A reference solution of sodium acetate 
buffer was introduced into the channel by pipetting 1 µL of solution into the inlet 
reservoir and applying a vacuum to the outlet well.  Once the solution had filled the 
channel, the flow was stopped and the backscatter signal, or binding event, was 
monitored for one minute.  This process was repeated iteratively for increasing 
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concentrations of the carbohydrate from 10–100 μM.  The channel was rinsed with 
sodium acetate buffer between each analyte sample to remove any bound sugar from the 
Con A; the BSI signal was always observed to return to the baseline value after such 
rinsing.  The same experiments were performed with CPMV particles (0–40 nM in 
capsids, 0–8 µM in attached sugar), Qβ virus-like particles (0–5 nM in capsids, 0–2.5 µM 
in attached sugar), generation-4 PAMAM dendrimers (0–2.5 µM in dendrimer, 0–100 
µM in attached sugar), and generation-6 PAMAM dendrimers (0–60 nM in dendrimer, 0–
5 µM in attached sugar). Wild-type CPMV and Qβ particles, as well as G4 and G6 
dendrimers bearing only galactose, were used as controls in order to rule out 
contributions from non-specific adsorption. 
 The competition data shown in Figure 3.9A, B were obtained from the following 
procedure.  A 32 nM solution of particle 11 was incubated in a standard extravidin/conA-
derivatized channel for one minute, during which time the signal stabilized at 
approximately 0.03.  The value indicated by the horizontal black line in each plot 
represents the average of these measurements throughout the experiment (standard 
deviation = 0.005).  A solution of conA or mannose, starting with the most dilute 
concentration, was flowed into the channel, displacing the solution of 11.  The change in 
signal was monitored for one minute; it reached the indicated value within 15 seconds.  
The channel was then rinsed extensively with buffer and the process was started again 
with a fresh 32 nM solution of 11, and the next highest concentration of reagent. 
 
 
 
36 
Data Analysis: 
 A correction must be made for the bulk refractive index change due to the 
presence of different concentrations of ligand in solution.  This is accomplished by 
recording a calibration curve for the ligand in the absence of immobilized protein (data 
not shown).  For each experiment, the observed phase change (corrected for bulk ligand 
effects) was plotted versus concentration in order to create a saturation binding curve.  
This endpoint analysis plot was then fitted to the square hyperbolic function (Langmuir 
isotherm) shown in Equation 1 using PrismTM software to obtain a value for (1/Kads). 
 S  S0  Smax  S0  L 1/Kads  L   (1) 
where S = corrected phase change in the presence of carbohydrate ligand, S0 = corrected 
phase change in the absence of ligand (buffer only), Smax = maximum corrected phase 
change in the presence of ligand (assumed to represent full binding to the immobilized 
protein), and [L] = concentration of carbohydrate ligand in solution.  Use of the Frumkin 
isotherm equation as described by Kiessling and coworkers27 gave no indication of 
attractive or repulsive interactions between the adsorbing molecules.  
 
Polymer Carbohydrate Adduct Preparation: 
 Cowpea mosaic virus (CPMV)137,138 and bacteriophage Qβ virus-like 
particles,139,140 both approximately 30 nm in diameter but very different in their structural 
details,141,142 were decorated with monosaccharides, as shown in Figure 3.3, by Eiton 
Kaltgrad at The Scripps Research Institute.  CPMV displays 240 lysine amine side chains 
on its exterior surface in solvent-accessible positions.143,144  Two forms of Qβ were used: 
the wild-type assembly domain sequence of the coat protein which displays up to 900 
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amine groups per particle, and the K16M mutation of this sequence which eliminates the 
most accessible lysine and therefore bears 720 surface amines.145  In both Qβ structures, 
some steric hindrance exists among sets of symmetry-related residues, diminishing the 
maximum number of carbohydrates that can be attached.  Polyvalent CPMV-glycan 
structures 7, 8, and 11 were prepared, bearing approximately equal numbers of α-
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Figure 3.3:  Polymer virus- and dendrimer-carbohydrate adducts. 
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mannose molecules but with different linkers.  CPMV particles (11 – 15) bearing 
different ratios of mannose and galactose, with the same overall loading of sugar, were 
also synthesized.  These structures were prepared using different ratios of mannose and 
galactose azides 3 and 4, assuming that the rates of the reaction are insensitive to the 
identity of the monosaccharide (Figure 3.3A).  In addition, Qβ structures 9 and 10 were 
made to test higher densities of sugar loading on the shortest linker arm.  Details of the 
virus particle preparation are in appendix A. 
 Generation 4 (G4) and generation 6 (G6) PAMAM dendrimers decorated with 
varying numbers of α-linked mannose and galactose units were prepared as previously 
described (Figure 3.3B).146   
 
Results and Discussion: 
 
Monovalent Interactions: 
 The interaction of biotinylated concanavalin A (conA), immobilized in the above 
manner, with its natural ligands was measured as a function of concentration, with the 
results shown in Figure 3.4A.  The phase change in the interferometry signal was found 
to vary in a manner consistent with dose-dependent saturation of a single binding site.  
The apparent Langmuir adsorption coefficients calculated from these curves (Kads = 
2.4±0.3 x 104 M–1, 1/Kads = 42±5 µM for D-mannose; Kads = 6.5±5.4 x 103 M–1, 1/Kads = 
155±88 µM for D-glucose)136 show the same relative trend, but stronger apparent 
binding, than true solution-phase equilibria (KD) that have been measured by ITC for the 
free sugars (Kd = approx. 450 µM for mannose and 1800 µM for glucose at room 
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temperature).13,27,28,34,35  The same type of discrepancy (but to a greater degree, 1000-fold 
vs. 10-fold) has been observed by Kiessling, Corn, and coworkers for immobilized 
glycosides in SPR measurements (1/Kads = 0.18±0.06 µM vs. Kd = 100-200 µM for α-Me-
mannose).27  Galactose induced no change in interferometry signal, consistent with its 
inability to bind to conA (Figure 3.4A).  In contrast, biotinylated BS-1 lectin used in the 
same manner responded to added galactose (1/Kads = 30.2 ± 2.8 µM),136 but not mannose, 
consistent with its known glycan affinities (Figure 3.4B).147-150  
 The observed Kads for the conA-mannose interaction was independent of both the 
source of the biotinylated lectin and its loading on the channel surface (Figure 3.5).  The 
binding of mannose to a surface of conA that was biotinylated in-house was compared to 
the binding to a surface of commercially purchased biotin-conA and very similar binding 
curves that produced the same affinty.  The number of conA molecules immobilized on 
the channel was reduced by treating the avidin-coated chip with a 1:1 mixture of biotin-
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Figure 3.4:  Measurement of monovalent carbohydrate binding to immobilized biotin-conA.  (A)
Comparison of sugars on immobilized commercial biotin-conA.  (B) Comparison of sugars on 
immobilized biotin-BS-1.  Error bars on all plots are derived from three independent experiments 
using different chips, showing a high degree of reproducibility.  
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conA and biotinylated bovine serum albumin (BSA).  BSI analysis of mannose binding in 
the two cases gave a diminished maximum signal in the mixed conA/BSA case, reflecting 
the expected dilution of glycan-binding protein on the surface.  However, the same 
binding constant was found in both cases, suggesting that each molecule of immobilized 
protein acts independently from the others, although the existence of binding sites having 
different affinities within each conA tetramer151 cannot be discerned from these data.  It 
is also noteworthy that once the channel is charged with lectin, the BSI measurements are 
made within minutes and are highly reproducible.  Added carbohydrate can be washed 
out with buffer and the immobilized lectins reused with no loss in signal or change in 
observed binding constant over at least 30 repetitions.  
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Figure 3.5:  Comparison of mannose binding to different sources of biotinylated conA (deposited 
at the same concentration): red squares = commercially available material; blue diamonds = conA 
biotinylated in-house; green triangles = an equimolar mixture of commercial biotin-conA and 
biotin-BSA.  
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Polyvalent Interactions: 
 As with any surface-based technique, BSI lends itself to measurements of 
polyvalent binding.116  To demonstrate this, icosahedral virus particles that have been 
previously employed for the presentation of polyvalent glycans to lectins, cell surfaces, 
and the avian immune system,152-154 as well as polyamidoamine (PAMAM) dendrimers 
decorated with monosaccharides, known to have a strong generational (size and valency) 
dependence on interactions with cognate lectins146,155,156 were studied. 
 Polyvalent CPMV-glycan structures 7, 8, and 11 have approximately the same 
number of α-mannose molecules, but with different linkers.  In addition, Qβ structures 9 
and 10 have higher densities of sugar loading utilizing the shortest linker arm.  The 
binding of these particles to immobilized conA was measured by BSI, with the results 
shown in Figure 3.6.136  The unmodified wild-type virions showed no interaction with the 
conA-derivatized surfaces, whereas the mannosylated particles were tightly bound.  On a 
per-mannose basis, the measured average adsorption coefficients were approximately 60 
times better for the CPMV-displayed sugar (Figure 3.6A) than for free mannose in 
solution (and thus likely to be 20-30 times better than α-Me-mannoside, which binds 
conA 2-3 times more tightly than mannose13,27,28,34,35).  On a per-particle basis, the virus 
adducts achieved avidities in the low nanomolar range.  For the same surface glycan 
density, the use of different linkers made no difference.  When displayed at a 
significantly higher density on the Qβ scaffold (Figure 3.6B), binding was further 
improved, with affinity approximately 200 times that of free mannose on a per-sugar 
basis, and sub-nM in terms of particle concentrations.  
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 Changes in polyvalent affinity were also conveniently determined by BSI for 
CPMV particles bearing different ratios of mannose and galactose, with the same overall 
loading of sugar.136  As shown in Figure 3.7A-B, particles 11 (bearing only mannose) and 
15 (bearing only galactose) were not bound by immobilized BS-1 and conA lectins, 
respectively, ruling out contributions from nonspecific adsorption by the linker and 
triazole moieties added to the coat proteins in the bioconjugation process.  In each case, 
the installation of mannose or galactose at 25% of the approximately 200 virus surface 
sites gave rise to highly potent binding to conA and BS-1, respectively, with modest 
increases in avidity of the particles observed as the percentage of active glycan was 
increased (Figure 3.7C-D, blue).  On a per-glycan basis, however, the affinities (while 
still much higher than the free sugars) were found to either decrease throughout the series 
for mannose-conA or decrease to an approximate plateau for galactose-BS-1 (Figure 
3.7C-D, black) as the loading of the active sugar on the virus surface was increased.  The 
magnitude of the increase in per-glycan affinity (60-200 times) suggests that true 
polyvalent binding (simultaneous multipoint interactions with more than one anchored 
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Figure 3.6:  Measurement of polyvalent virus-carbohydrate binding to immobilized biotin-conA.
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receptor) is taking place.155,156  A summary of the measured binding constants used in 
Figure 3.7 C-D are shown in Table 3.1.136  It is noteworthy that the binding avidities 
measured for the galactose-labeled particles to BS-1 are on the same order as mannose 
particles to conA, in spite of the fact that the weaker-binding β-anomer of galactose was 
used on the particles.149  This also supports the assignment of polyvalency to these 
interactions of virus-glycans with surface-tethered lectins. 
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Figure 3.7:  Binding of mixed mannose-galactose virus particles to immobilized conA and BS-1 
lectins.  (A, B) BSI measurements of the binding of the indicated CPMV-(sugar)192 particles to 
immobilized conA and BS-1.  (C, D) Plots of values of 1/Kads derived from A and B, in terms of 
the overall concentrations of the indicated glycan presented on the virus surface (black) and the 
concentrations of the virus particles (blue).  In all cases, 1/Kads values were calculated from each 
curve independently, ignoring the relative differences in signal magnitudes between curves. 
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Table 3.1:  Measured binding constants of polyvalent glycan virus particles 
0.15 ± 0.0240.80 ± 0.13no bindingno binding15
0.16 ± 0.0161.1 ± 0.110.23 ± 0.0214.8 ± 0.4414
0.14 ± 0.0151.5 ± 0.160.33 ± 0.0313.4 ± 0.3213
0.084 ± 0.00941.8 ± 0.200.39 ± 0.0422.7 ± 0.2912
no bindingno binding0.42 ± 0.0682.2 ± 0.3511
1/Kads of per galactose 
to BS-1 (µM)
1/Kads of particles to 
BS-1 (nM)
1/Kads per mannose to 
conA (µM)
1/Kads of particles to 
conA (nM)
Polyvalent 
Glycan
 
 
 
 To extend the observation of polyvalent binding, generation 4 (G4) and 
generation 6 (G6) PAMAM dendrimers decorated with varying numbers of α-linked 
mannose and galactose units were studied.  BSI measurements with immobilized conA 
were again sensitive and highly reproducible, with signal magnitude depending on the 
number of mannose units loaded onto each dendrimer, and the measured adsorption 
coefficients sensitive to dendrimer size (Figure 3.8).136  The G4-based particles showed 
per-mannose affinities (1/Kads ≈ 20 µM) approximately twice the measured values for 
mannose alone, and thus exactly what one would expect for monovalent α-
alkylmannoside.  Neither the per-mannose nor the per-particle affinity (1/Kads ≈ 0.5 µM) 
changed appreciably with variation in mannose loading from 18 to 42 per dendrimer 
(Figure 3.8C).  In contrast, the G6 dendrons did show a modest improvement in per-
mannose adsorption coefficient from 10.0 ± 3.4 µM (for 24, with 31 mannoses) to 2.8 ± 
0.4 µM (for 21, with 111 mannoses) as mannose loading increased.  Similarly, the per-
dendrimer association constants improved through the G6 series (Figure 3.8D; 24, 1/Kads 
= 84 ± 29 nM, to 21, 1/Kads = 25.8 ± 4.1 nM).  The “proximity effect” from the 
presentation of high local concentrations of glycan ligands on the dendrimer surface to 
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individual immobilized lectins can be expected to contribute to the improved avidity of 
dendrimer-glycan conjugates.100,146,157  However, the fact that even the most lightly-
loaded G6 structure shows better binding than the G4 dendrimers that are more densely 
decorated with glycan suggests that the G6 particles interact with the immobilized conA 
in a different manner than G4.  Such interactions are presumably bi- or polyvalent, either 
with individual conA lectins (G6 being able to reach two binding sites better than G4) or 
with adjacent conA molecules.  A summary of the measured binding constants used in 
Figure 3.8 C-D are shown in Table 3.2.136   
0 20 40 60 80 100
0.00
0.01
0.02
0.03
0.04
0.0 1.0 1.5 2.5
Dendrimer Concentration (nM)
G4 16
17
18
19
20
Man/Gal
42/0
38/9
31/10
18/31
0/42
Total Sugar Concentration (M)
Ph
as
e 
C
ha
ng
e
(r
ad
ia
ns
)
0.5 2.0
15 20 25 30 35 40 45
15
20
25
30
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
G4
16
16
17
17
18
18
19
Number of Mannose per Particle
1/
K
ad
s 
(M
an
)(
M
)
1/K
ads  (dendrim
er) ( M
)
20 40 60 80 100 120
0
5
10
15
20
40
60
80
100
120
G6
21
22
23
24
Number of Galactose per Particle
1/
K
ad
s 
(G
al
)(
M
)
1/K
ads  (dendrim
er) (nM
)
A B
C D
0 1 2 3 4 5
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0 18 27 45
Dendrimer Concentration (nM)
G6 21
22
23
24
Man/Gal
111/0
86/33
53/33
31/88
9 36
Total Sugar Concentration (M)
Ph
as
e 
C
ha
ng
e
(r
ad
ia
ns
)
Figure 3.8:  Binding of mixed mannose-galactose dendrimers to immobilized conA and BS-1 
lectins.  (A, B) BSI measurements of the binding of the indicated G4 and G6 dendrimer-(sugar)n 
particles to immobilized conA.  (C, D) Plots of 1/Kads derived from E and F.  In all cases, 1/Kads
values were calculated from each curve independently, ignoring the relative differences in signal 
magnitudes between curves.  
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Table 3.2:  Measured binding constants of polyvalent glycan dendrimer particles 
10.0 ± 3.483.8 ± 29.024
7.5 ± 1.086.2 ± 11.923
4.4 ± 0.736.7 ± 5.722
2.8 ± 0.425.8 ± 4.121
22.6 ± 3.4460 ± 7019
18.9 ± 2.2460 ± 5018
18.9 ± 2.2400 ± 5017
19.8 ± 1.6470 ± 4016
1/Kads per mannose to 
conA (µM)
1/Kads of particles to 
conA (nM)
Polyvalent 
Glycan
 
 
 
 It has previously been demonstrated by agglutination and precipitation assays that 
both the G4 and G6 dendrimers used here, but not G3 or smaller structures, are able to 
engage conA units in polyvalent binding interactions in solution.146  In the BSI 
measurements described above, however, G4 glycan dendrimers are monovalent binders 
and G6 dendrimers only begin to show polyvalent-style affinities, whereas the virus-
based structures bind much more tightly.  The most obvious distinguishing characteristic 
among these polyvalent ligands is their size: G4 dendrimers, G6 dendrimers, and the 
virus capsids have approximate diameters of 5, 7, and 30 nm, respectively.  The avidin 
tetramer occupies a volume of approximately 5 x 5 x 6 nm,158 and is likely to be affixed 
to the glass-NHS ester surface in an orientation that blocks at least two of its biotin 
binding sites from solution.159  The density of surface attachment points for biotinylated 
lectin should therefore be quite low, and adjacent lectins would be reachable for 
polyvalent binding only by the larger glycosylated structures.  Multivalent binding to 
individual adsorbed conA tetramers will be difficult for these dendrimers and virus 
particles which have short tethers connecting the sugar to the platform.146  
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 The most important difference between the BSI technique and methods such as 
SPR and QCM concerns the nature of the signal: BSI detects changes in refractive 
index,91 and is thus sensitive to the number of binding events rather than the change in 
mass brought about by binding.  For example, the maximum (saturation) signal for 
polyvalent particles, such as viruses and dendrimers, was found to be proportional to the 
number of binding ligands attached to the scaffold (mannose vs. galactose, for example, 
in Figures 3.7A, B and 3.8A, B), even though the maximum number and mass of particles 
that can access the surface was the same for all members of the series.  In contrast, one 
could not distinguish by SPR at surface saturation between particles bearing different 
numbers of binding ligands.  The mass change in such a measurement would be equal in 
all such cases, regardless of how many receptor-ligand binding events occur, except for 
water displaced from each protein binding site upon interaction with the ligand.  Because 
BSI detects changes in refractive index, it is sensitive to that water displacement.  For this 
reason, the magnitudes of the phase changes observed for the saturation of the 
immobilized proteins with monovalent sugars are greater than those observed for binding 
of the massive virus- or dendrimer- displayed structures (Figures 3.4 and 3.5 vs. Figures 
3.6, 3.7, and 3.8).136 
 This difference in the nature of the signal also manifests itself when species are 
removed from the surface.  If one washes a large molecule off an SPR chip, the signal 
invariably decreases due to the loss of attached mass.  With BSI detection, the signal 
depends on which species is used to do the washing, as shown in Figure 3.9.  When 
soluble conA was used to remove CPMV-mannose (11) from the standard extravidin-
conA channel, a dose-dependent decrease in signal was observed, consistent with the 
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competitive stripping away of the virion from the surface by the soluble receptor (Figure 
3.9A).  One could in principle use this phenomenon to measure solution-phase 
association constants by competitive binding, as has been done with SPR imaging.27  In 
contrast, the addition of soluble mannose (Figure 3.9B) gave rise to an invariant increase 
in signal, even when the mannose concentration (20 µM) was well below the KD value 
for free mannose-conA binding (42 ± 6 µM).  At that concentration (and probably higher 
concentrations as well), mannose cannot be expected to dislodge virus particles that bind 
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Figure 3.9:  BSI measurement of the treatment of CPMV-mannose particle 11 bound to an 
extravidin-conA channel with increasing concentrations of (A) soluble conA and (B) mannose. 
(C) Cartoon representation of experiments measuring binding and competition with free sugar 
and receptor.  For particles bearing different numbers of sugars, saturation is reached with 
approximately the same number of virions bound, and yet the signal intensities in the two cases 
are markedly different. 
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with much greater affinity (KD = 2.2 ± 0.36 nM in virions; 0.42 ± 0.07 µM per mannose).  
The interferometry signal increases because mannose occupies empty conA binding sites 
that are underneath virus particles attached to the surface.  In this case, it is impossible to 
tell when virus is outcompeted by added mannose for surface conA sites, since the signal 
does not change.  Figure 3.9C summarizes in graphical form the various states achieved 
when large polyvalent ligand particles compete with soluble ligand or receptor for surface 
receptor sites, highlighting the dependence of BSI signal on the number of receptor-
ligand binding events occurring at the surface of the channel. 
 
Conclusions: 
 Back-scattering interferometry uses simple hardware to achieve highly sensitive 
measurements of protein binding events on very small amounts of material in a reusable 
format.  Here its application to the quantitative determination of adsorption coefficients, 
and the relative determination of binding constants and polyvalent avidities, for glycan-
lectin interactions, one of the most important classes of interactions in biochemistry, has 
been demonstrated.  The receptor has been attached to the BSI channel by a general 
method involving complexation with an intervening layer of avidin, providing relatively 
large spacing between attachment sites and an environment conducive to the maintenance 
of native structure and function. 
 The interferometric response detects the act of complexation without direct regard 
to the size of the species doing the binding.  This is consistent with BSI’s known 
sensitivity to changes in refractive index.91  It is presumed that conformational changes in 
the tethered binding partner and/or expulsion of bound water caused by ligand binding 
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contribute to refractive index modulation.  The technique therefore gives rise to very 
different types of responses to polyvalent interactions, detecting the total number of 
binding events whereas SPR and QCM report on the fate of the polyvalent structure as a 
whole.  Given its technical simplicity, high sensitivity, and label-free nature, it is 
expected that BSI will find use in the quantitative exploration of glycan-receptor 
interactions in a variety of contexts. 
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CHAPTER IV 
 
BACKSCATTERING INTERFEROMETRY FOR THE POTENTIAL USE IN 
DISEASE DIAGNOSITICS UTILIZING SYPHILIS AS AN EXAMPLE 
 
Background and Significance: 
 Backscattering interferometry (BSI) is a versatile sensing technique and has been 
developed for a wide array of applications.81,84-87,89,160,161  BSI has most recently been 
employed to study molecular interactions in a label-free method and has been used to 
investigate binding events in both a surface-immobilized scheme and in free 
solution.91,93,136,162  The ability of BSI to measure interactions rapidly using picoliter 
detection volumes in a free-solution format makes BSI unique among sensing techniques, 
eliminating time and monetary costs related to labeling and immobilization strategies.  
BSI will now be applied to disease-detection strategies with the potential application as a 
reactive serum detector.  For these studies, syphilis serology will be used as a model for 
evaluating the diagnostic performance of BSI. 
 Current diagnostic tools rely heavily on labeling with signaling moieties to detect 
the presence of a particular antigen or antibody in a sample.  Such chemical labeling not 
only consumes time and resources, but may also alter the conformations and/or behavior 
of binding partners, obscuring test results.163  Introducing this variable necessitates that 
many common label-based diagnostic assays must be corroborated by additional testing 
methods, further increasing time, cost, and sample consumption.164   
 Current methods for the detection of many diseases, such as syphilis, include cell 
cultures, ELISA (enzyme-linked immunosorbent assays), nucleic acid amplification tests 
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(PCR and LCR), and direct immunofluorescence (DIF).  These methods often require the 
patient samples to be sent off to a lab for analysis, which may take several days.  This 
procedure causes a delay in treatment and, in some instances, the patient does not even 
return for treatment.  The lack of a rapid test often results in the empirical use of 
antibiotics, which may be prescribed in error.  If a method were available to diagnose a 
disease in the doctor’s office, the correct treatment could begin immediately.   
 The enzyme-linked immunoassay (ELISA) is a widely-used diagnostic tool which 
relies heavily on signaling moieties to detect the presence of a particular antigen or 
antibody in a sample.  This technique has become a standard diagnostic strategy for 
numerous critical diseases, including syphilis.164-166  Syphilis diagnostics are particularly 
sensitive to time, cost, and sample volume considerations because of their heavy presence 
worldwide, including developing areas.  Therefore, a label-free microfluidic diagnostic 
tool has the potential to revolutionize point-of-care diagnostics for these and other 
widespread diseases.  
 Of the available label-free techniques, BSI provides unmatched sensitivity and is 
the only tool that is fully compatible with microfluidics – critical advantages for 
diagnostic applications.91  Using BSI to detect antigen-antibody interactions has the 
advantage of not only decreasing cost, time, and sample volume considerations, but also 
offering the unique potential to quantify antibody levels in clinical samples.  Such an 
advantage may provide valuable information concerning disease status, severity, 
progression, and/or therapeutic efficacy.  In order to explore BSI’s capacity to detect 
syphilis infection in human sera, purified antigens will be used to detect antibodies in the 
sera raised against the infection (Figure 4.1).  The ability to detect antigen-antibody 
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interactions with BSI has previously been established by the Bornhop group.91  
Successful detection of syphilis infection in human specimens using BSI will not only 
provide innovative diagnostic approaches for this particular disease, but will serve as a 
benchmark in protein-based diagnostics, applicable to countless other diseases.   
 Syphilis is a sexually transmitted infectious disease caused by the bacterium 
Treponema pallidum for which no adequate in vitro culturing method has been 
developed.167,168  Therefore, current syphilis diagnostic tests typically rely on the 
detection of anti-treponemal antibodies raised against the pathogen itself (i.e., treponemal 
tests) as well as nontreponemal tests for antibodies against lipoidal material released from 
damaged host cells and against lipoprotein-like secretions of the treponeme.167,168  The 
most commonly used treponemal tests include fluorescent treponemal antibody 
absorption (FTA-ABS) and the treponemal pallidum particle agglutination test (TP-PA), 
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Figure 4.1:  Illustration of the method used to detect the presence of disease in human serum 
samples. 
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and current nontreponemal tests include the Venereal Disease Research Laboratory 
(VDRL) and the Rapid Plasma Reagin (RPR) tests.167,168  While treponemal tests are 
highly specific, they give little or no indication of the status of the infection because anti-
treponemal antibodies are retained for a lifetime.  In contrast, nontreponemal tests are 
most reactive during active syphilis infection; when the disease is latent or has been 
effectively treated, the reactivity of the antiserum to these tests subsides.167  However, 
nontreponemal tests have shown a high rate of false-positive results (i.e., are relatively 
nonspecific) because anti-cardiolipin antibodies may be generated as a result of 
conditions unrelated to syphilis, including autoimmune diseases, tuberculosis, pregnancy, 
and vaccinations.169  Therefore, it is most informative to perform a treponemal and a 
nontreponemal diagnostic test in concert; a typical clinical diagnosis may be based upon 
an RPR or VDRL screening followed by a TP-PA or FTA-ABS confirmation.168    
 Each of these diagnostic tests relies on a visual interpretation of results and/or 
labeling.  The FTA-ABS utilizes the reaction of fluorescently-labeled anti-IgG antibodies 
with anti-treponemal serum antibodies bound to an antigen-coated slide, detected using 
fluorescent microscopy.  The TP-PA test employs antigen-coated colored gelatin particles 
to visualize the hemagglutination of reactive antiserum (Figure 4.2170).  The VDRL test 
evaluates the level of clumping between antiserum and an antigen containing cardiolipin, 
lecithin, and cholesterol as seen under a visible light microscope.167,168  The RPR test 
utilizes charcoal as a visualizing agent to detect this same clumping reaction with the 
naked eye (Figure 4.2170).  The application of BSI to syphilis diagnostics would enable 
both treponemal and nontreponemal tests to be performed rapidly in a single low-volume 
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assay format without the use of fluorescent tags, visualizing agents, or microscopy, as 
well as decreasing time and cost considerations. 
 
Blind Assay: 
 Through a collaboration with the Sexually Transmitted Disease (STD) division of 
the Centers for Disease Control and Prevention (CDC), samples for a blind assay, 
including four human serum samples (1 – 4) and four syphilis antigens (A – D), were 
received.  The serum samples were from patients with different titer values (negative, low 
titer, medium titer, and high titer) based on the standard RPR test.  The antigens were 
three different protein conjugated cardiolipin antigens and a treponemal antigen, all at a 
10 µg/mL concentration.  Cardiolipins are used as antigens to detect antibodies in the 
serum that are created as a result of the damage caused to the host cells.167  The 
Negative
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TP-PA RPR
 
Figure 4.2:  Images of positive and negative results using the TP-PA and RPR tests. 
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treponemal antigen (r17) is a recombinant protein antigen with a molecular weight of 17 
kDa that mimics the proteins found on the surface of the treponemes.   
 The initial experiment set up was an endpoint analysis of the combinations of the 
four serum samples with the four antigens, utilizing the borosilicate glass chips 
manufactured by Micronit previously described (Chapter III).  The serum samples were 
first diluted with PBS in a 1:10 ratio (30 µL serum + 300 µL PBS).  Equal amounts of the 
diluted serum and the antigen (15 µL diluted serum + 15 µL antigen) were then 
thoroughly mixed to yield a solution that had a final serum dilution of 1:20 and a final 
antigen concentration of 5 µg/mL.  The mixture was then introduced into the channel and 
the BSI measurements were taken of all 16 samples and plotted versus serum number for 
each antigen.   
 The average phase values of the serum – antigen mixtures were plotted versus 
serum number and are shown in Figure 4.3.  As expected, the trend of the serum samples 
was consistent for each antigen.  The trend indicates the order of reactivity for the serum 
samples for the antigens; however, it is not possible to differentiate the sera samples or to 
determine which is the non-reactive serum and which is the high-reactive serum.  
Therefore the order according to reactivity is either serum 1 < serum 4 < serum 3 < serum 
2 or serum 2 < serum 3 < serum 4 < serum 1. 
 This limitation is due to the fact that, without prior knowledge, the fringes can 
shift either to the left or to the right depending on the change in RI and that binding 
interactions can cause either an increase or decrease in RI.  The source of the signal 
detected by BSI is still under investigation, but is thought to arise from changes in 
conformation, waters of hydration, and molecular dipoles.91  The effects of binding on 
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these properties is not immediately predictable and can result in an increase or decrease 
in the BSI signal.  In short, without previous knowledge of the binding system or a 
known blank sample, the phase change can be positive or negative as the reactivity of the 
sample increases.  Of course, in a real assay, calibrations and controls would eliminate 
this limitation. 
 Utilizing the ability of BSI to perform real-time measurements, a kinetic analysis 
was performed in a manner similar to the interleukin-2 assay in Chapter II.  This 
experiment utilized a chip, also manufactured by Micronit that had an on-chip serpentine 
mixer (Figure 4.4).  The diluted serum was introduced into one inlet and the antigen was 
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Figure 4.3:  BSI measurements of the blind assay endpoint analysis. 
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introduced into the second inlet.  The samples were then drawn through the channel with 
a vacuum, mixing the pair and allowing the binding event to be observed in near-real 
time.  By observing the magnitude and direction of the binding isotherm, this assay 
allowed for the assignment of the relative titer strengths of the samples.  The serum 
sample that consistently showed the largest binding signal would have the highest relative 
concentration of antibody and, therefore, the highest titer. 
 The kinetic assay showed a consistent decrease in phase as the antibody and 
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Figure 4.4:  Microfluidic mixer chip used in the kinetic analysis experiments. 
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Figure 4.5:  A sample of the real-time binding curves observed during the kinetic analysis. 
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antigen bound.  A representative trace of the binding curves for all of the serum samples 
is shown in Figure 4.5.  The magnitude of the change was confounded slightly by 
inconsistencies in the mixing due to the difference in viscosities of the serum and the 
antigen solution and by protein adhesion to the surface of the channel.  However, the 
overall trend showed the largest binding signal for serum 2 indicating that it had the 
highest reactivity.  The relative strength of the sera samples could then be determined 
from the trend observed in the endpoint assays resulting in the following assignments: 
 Serum 1 = Non-Reactive 
 Serum2 = High Reactive 
 Serum 3 = Mid Reactive 
 Serum 4 = Low Reactive 
 The results from BSI were compared to the known titers of the blinded serum 
samples based on the standard RPR test performed by the CDC (Figure 4.6).  It was 
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Figure 4.6:  Results of the ELISA scan provided by the CDC. 
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determined that our ranking of the sera samples was correct: serum 1 was a negative 
sample, serum 2 was an R32 sample, serum 3 was an R8 sample, and serum 4 was an R2 
sample (Figure 4.7). 
 
Micellar Cardiolipin Antigen: 
 A micelle is an aggregate formed by molecules with hydrophilic head regions and 
hydrophobic tail regions.  The molecules arrange themselves in a typically spherical 
formation, so that the hydrophobic tails are protected from the aqueous environment by 
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Figure 4.7:  Adjusted BSI measurements of the blind assay endpoint analysis illustrating the 
consistent trend, in agreement with the ELISA results. 
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the hydrophilic head groups (Figure 4.8).  The micellar cardiolipin antigen is a synthetic 
antigen containing cardiolipin, cholesterol, and lechithin which is designed to mimic the 
lipoidal material secreted from damaged host cells and from the treponeme itself.167  It 
has been developed by the CDC in order to increase the sensitivity of the non-treponemal 
agglutination tests.  The next experiment tested the use of the micellar cardiolipin antigen 
for BSI measurements.  The micellar antigen was diluted in a 1:500 ratio with PBS (1 µL 
antigen + 500 µL PBS) and mixed in even amounts with the diluted serum, yielding a 
solution that had a final serum dilution of 1:20 and a final antigen dilution of 1:1000.  
The results of the analysis had the same trend as the titer strength calculated using the 
standard RPR test with a traditional cardiolipin antigen (Figure 4.9).  This analysis 
further shows that BSI has the potential to be a quantitative test for the presence of 
antibodies in clinical samples.   
 
Treponemal Antigen: 
 In order to evaluate the performance of BSI in determining the reactivity of 
clinical samples, the treponemal antigen experiments were expanded to include multiple 
 
Figure 4.8:  Image of a micelle. 
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clinical samples.  The samples used in this experiment were previously classified as 
positive or negative using the treponemal particle agglutination (TP-PA) test by the CDC.  
The serum samples were first diluted with PBS and were then mixed with the r17 
treponemal antigen to yield a solution that had a final serum dilution of 1:20 and a final 
antigen concentration of 5 µg/mL.  The samples were incubated for one hour at room 
temperature.  The binding signal of the interaction was measured and plotted versus the 
serum classification (Figure 4.10).  These results show a strong statistical difference (p = 
2·10-6) between signals for positive and negative samples using the treponemal r17 
antigen.  This data demonstrates that a signal threshold may be established for 
determining the reactivity of unclassified samples.   
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Figure 4.9:  Results of the interaction of the serum with the micellar cardiolipin antigen; error 
bars represent the noise within the measurement.  The results show a good correlation with the 
titers determined by the standard RPR test. 
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Conclusions: 
 The experiments performed using human serum samples demonstrate that BSI 
may be capable of serving as a reactive serum detector in a clinical setting.  There was a 
clear threshold between reactive and nonreactive sera determined for a panel of samples 
using a treponemal antigen.  Additionally, the BSI signal arising from the binding of the 
antiserum and the nontreponemal antigens shows a strong correlation with the semi-
quantitative RPR test currently in practice.  These results show promise for utilizing BSI 
to perform rapid serological tests using a variety of molecular probes, offering endless 
possibilities for multiplexed, quantitative assays to improve current clinical diagnostics 
and therapy monitoring applications. 
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Figure 4.10:  A. Treponemal results in twelve clinical samples.  B. Average signal for positive 
and negative samples showing a clear separation (p = 2·10-6). 
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CHAPTER V 
 
MEMBRANE ASSOCIATED BINDING STUDIES PERFORMED UTILIZING 
BACKSCATTERING INTERFEROMETRY 
 
Background and Significance: 
 Lipid bilayer membranes are naturally-occurring, two-dimensional fluids 
comprised of stringently regulated combinations of molecules, such as phospholipids and 
proteins.  This molecular architecture of membrane-associated proteins is ubiquitous 
within all living organisms.  Molecular interactions occurring at or on these proteins 
occur only within the well-defined chemical environment afforded by the surrounding 
lipid bilayer membrane.  This two-dimensional fluid not only serves to isolate a cell from 
its external environment, but also provides the spatial, temporal, and chemical control 
critical for these events to occur.  The molecular interactions occurring at the membrane 
are constantly transformed into gross physiological phenotypes through a combination of 
spatially-regulated binding events and transduction of the resulting signal across the 
membrane barrier.171  As a result, membrane-associated proteins and their interactions 
remain of great interest to the design of clinical therapies, accounting for almost 70% of 
existing drug candidate targets.172  Though a plethora of assays exist to examine binding 
events, for this class of molecular interactions, the targets of interest must typically 
undergo covalent modification and removal from the native membrane environment prior 
to observation.  Techniques such as direct labeling, surface coupling, and genetic 
modification, while necessary for quantitative analysis, are known to affect a target’s 
function in unpredictable ways, pose experimental hazards, and are not uniformly 
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applicable to all targets.173  BSI’s ability to study homogeneous binding events91 will now 
be employed to study membrane-associated interactions in a label-free solution-based 
format. 
 In the simplest case, optically compatible synthetic lipid membrane-based 
materials can be created that allow for well-defined display of chemical and biological 
moieties within the context of a fluid lipid bilayer.174,175  By introducing a binding target 
into membranes during the organic mixing phase, a population of small, unilamellar 
vesicles (SUVs) containing a uniformly-distributed population of solution-accessible 
ligands was created.  By controlling the incorporation of specific lipids in the organic 
phase, the population of created vesicles can be made to retain the characteristic fluidity 
of native membranes (Figure 5.1).  In this case, the monosialoganglioside GM1 was used 
 
 
 
Figure 5.1:  Schematic illustration of the SUVs containing the binding motifs within the lipid 
bilayer (black) incubated with the cognate ligands (green). 
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as the target molecule to be embedded into the membrane; GM1 is a target for the cholera 
toxin.  The B subunits of the cholera toxin (CTB) bind to the pentasaccharide region of 
the GM1 and initiate the intoxication of the host cell.176,177  This interaction is 
characteristic of most bacterial toxins and has been well studied in the testing of potential 
inhibitors.176-178   
 It is also possible to incorporate full-length, non-recombinant membrane proteins 
into membranes.179,180  Through the detergent solubilization and dialysis, a population of 
proteins can be introduced into a lipid bilayer membrane of synthetic origin.  The 
resulting materials have been shown to retain the in vivo characteristics of both ordered 
structure and fluidity, thus maintaining the activity of the associated proteins.  Though 
deposited onto supported monolithic substrates is a common technique for observing 
purified membrane proteins, transmembrane proteins usually suffer from restricted 
movement with this strategy, presumably due to the interactions occurring with the 
underlying surface.181-184  In fact, it is common to truncate such proteins by attaching a 
membrane-compatible insertion tag, such as a long-chain alkane, to preserve fluidity, thus 
conserving the functional elements of such proteins.  By using SUVs in combination with 
full-length proteins, we can preserve the natural fluidity of the membrane and 
consequently allow the proteins unrestricted diffusive properties along the surface of the 
membrane.  Additionally, we do not compromise the functionality of such proteins 
through biochemical alteration.  For these experiments, the transmembrane protein Fatty 
Acid Amide Hydrolase (FAAH) was incorporated into the SUV bilayers and its binding 
to several inhibitors was studied.  This particular catabolic enzyme has substantial roles 
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in many neurological phenotypes, primarily nociception.185  FAAH inhibitors have shown 
promise as analgesics and as therapeutics for neuropsychiatric disorders.186,187  
 Since it is not always possible or efficient to extract proteins from all native cells, 
a common method of determining ligand binding to cell membrane-associated proteins is 
to study downstream cellular responses in whole cells or to use radioactive assays on cell 
lysates.  Although considered to be the most suitable environments for the retention of 
correct membrane composition (and as a result, retention of membrane protein binding 
behavior) such assays cannot provide a method for examining binding directly and 
without labels.  However, by separating the outer membranes of the cell from the 
intracellular components and converting the membranes into vesicle-like suspensions of 
uniform size (Figure 5.2), we can render the membranes, with all their constituents, 
compatible with the BSI instrument without the need for protein purification or 
alteration.188,189  To investigate this possibility, a cell line genetically modified to express 
the G-protein-coupled receptor (GPCR) of B-form gamma-aminobutyric acid receptor 
(GABA-B) was utilized.  This protein has been implicated in many neurological disease 
 
 
Figure 5.2:  Schematic of creation of membrane SUVs. Cells are incubated in a hypotonic 
solution, gently lysed, and the internal components separated from the outer membranes through 
centrifugation.  Outer membranes are then sonicated and centrifuged to create a uniform 
population of SUVs. 
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phenotypes and has become a promising drug target.190-192  However, GABA-B retains 
the characteristic purification difficulties and low conformational stability that are 
common to all GPCRs that have been removed from the membrane.  The binding of 
GABA-B to a variety of substrates, including the known binder of gamma-aminobutyric 
acid, two known agonists (SKF-97541, and R-Baclofen), and one known antagonist 
(CGP-54626), was interrogated.   
 
Experimental Procedure: 
 SUVs were formed using standard techniques by Michael Baksh at the Scripps 
Research Institute (Appendix B).  Ligand binding to the SUVs was accomplished by 
incubating a fixed amount of SUV suspension with varying concentrations of different 
ligands (Table 5.1).  Control solution containing SUVs that did not contain the receptor 
were also prepared.  Ligand and SUV solutions were mixed and allowed to bind for 8 
hours at 4oC. 
 The BSI instrument was set up as previously described using a borosilicate glass 
chip manufactured by Micronit.  The control SUV – ligand solution was introduced into 
the channel and the BSI signal was measured for 15 seconds.  The receptor SUV – ligand 
solution was then introduced into the channel and the signal measured.  The channel was 
then rinsed and the procedure was repeated iteratively for increasing ligand 
concentrations.  The binding signal was calculated as the difference in phase between the 
control SUV – ligand solution and the receptor SUV – ligand complex (Figure 5.3).  The 
background signal due to the presence of the SUVs was subtracted from all 
measurements.  This corrected binding signal was then plotted versus concentration to 
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form a saturation binding curve and fitted to a square hyperbolic function to calculate the 
KD value. 
 
Results and Discussions: 
 The interaction between CTB and membrane-bound GM1 was measured and the 
results are shown in Figure 5.4A.  The data was fitted with a single-site binding model 
and dissociation constant (Table 5.2) was found to be 129 ± 27 pM (R2 = 0.94).  Tetanus 
Table 5.1:  Membrane-bound receptors and ligands studied. 
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toxin (TT) was used a control and showed little binding to the GM1 vesicles.  This value 
is consistent with established measurements obtained from other experimental systems, 
such as SPR and supported lipid bilayers.176,178   
 The results of the measured interaction of FAAH with the inhibitor molecules are 
shown in Figure 5.4B-D.  The KD values determined (Table 5.2) for these interactions 
were: 128 ± 22 pM (R2 = 0.85) for FAR-I-216, 264 ± 36 pM (R2 = 0.86) for OL-135, and 
4.1 ± 1.7 µM (R2 = 0.89) for JG-II-145.  Cholesterol was used as a control for all the 
pairs and showed little to no binding in all cases.  It should be noted that our observed 
KD’s differ substantially from what has been demonstrated previously in the literature.193  
However, the difference may be due to the fact that these previous measurements were 
performed on a truncated version of FAAH and utilizing methods of analysis that 
involved mixtures of organic and aqueous solvents in an attempt to stabilize the protein.  
While it is possible to solubilize an amphipathic transmembrane protein in a combination 
of solvents, a two-solvent configuration is probably not representative of the native 
Table 5.2:  Calculated KD values and literature affinity measurements for the membrane-bound 
receptor interactions. 
Kd = 7.7 nM
EC50 = 150 nM
IC50 = 48 nM
Kd = 38.6 nM
Ki = 10 μM
Ki = 48 nM
Ki = 53 nM
Kd = 4.61 pM
Ki = 13 nM
Literature
Affinity
5.4 ± 1.7 nMCGP-54626
20 ± 7.1 nMSKF-97541
208 ± 34 nMBaclofen
139 ± 65 nMGABA
GABA-B
4.1 ± 1.7 μMJG-II-145
264 ± 36 pMOL-135
128 ± 22 pMFAR-I-216
FAAH
129 ± 27 pMCTBGM1
KD
DeterminedLigand
Membrane Bound
Receptor
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Figure 5.3:  Illustration of the calculation of the (A) control signal and (B) binding signal of the 
ligand – membrane-bound receptor interactions. 
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membrane environment.  Consequently, the protein will likely display binding 
characteristics that differ from those observed when the protein is in its native membrane 
environment.  Additionally, our binding measurements are measured directly, without the 
 
 
0.5 1.0 1.5
0.000
0.005
0.010
0.015
OL-135
Cholesterol
10 20 30
Concentration (nM)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
0.5 1.0 1.5
0.000
0.005
0.010
0.015
FAR-I-216
Cholesterol
10 20 30
Concentration (nM)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
2.5 5.0
0.000
0.004
0.008
0.012
0.016
CTB
TT
50 75 100
Concentration (nM)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
A B
C D
E F
G H
5 10
0.000
0.005
0.010
0.015
JG-11-145
Cholesterol
150 200 250 300
Concentration (M)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
25 50 75 100
-0.007
0.000
0.007
0.014
0.021
0.028
SKF
Alanine
500 1500 2500
Concentration (nM)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
2.5 5.0
-0.005
0.000
0.005
0.010
0.015
Baclofen
Alanine
20 30 40 50
Concentration (M)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
10 20 30
0.00
0.01
0.02
0.03
GABA
Alanine
100 200 300
Concentration (M)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
10 20 30 40 50
-0.005
0.000
0.005
0.010
0.015
CGP-54120
Cholesterol
200 300 400 500
Concentration (nM)
Ph
as
e 
C
ha
ng
e 
(r
ad
)
Figure 5.4:  Binding curves obtained for all experiments (red squares).  Description of binding 
partners: (A) GM1-CTB; (B) FAAH – FAR-1-216; (C) FAAH - OL-135; (D) FAAH – JGII-145; 
(E) GABA-B – GABA; (F) = GABA-B – Baclofen; (G) NCM – SKF-97541; (H)= NCM – 
CGP-54626.  Controls showed little to no binding (blue triangles).  Description of the controls: 
(A) TT; (B-D) cholesterol; (E-G) alanine; (H) cholesterol. 
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use of labels, which are currently employed to characterize these binding systems.  
Furthermore, existing assays for FAAH-ligand binding measurements generally tend to 
rely on downstream signals, such as enzymatic activity, to determine binding affinities.  
 The reactions between the GABA-B contained in native cell membranes and 
several ligands were quantified and the results are shown in Figure 5.4E-G.  The 
dissociation constants (Table 5.2) were calculated from the curves and found to be: 139 ± 
65 nM (R2 = 0.86) for GABA, 208 ± 34 nM (R2 = 0.97) for baclofen, 20 ± 7.1 nM (R2 = 
0.88) for SKF-97541, and 5.4 ± 1.7 nM (R2 = 0.92) for CGP-54626.  Alanine was used as 
a control for GABA, baclofen, and SKF-97541 and cholesterol was a control for CGP-
54626.  In all cases, the control showed little to no binding.  The calculated KD values 
agree well with existing data of radioactive displacement and competitive binding 
assays.194,195   
 
Table 5.2:  Calculated KD values and literature affinity measurements for the membrane-bound 
receptor interactions. 
IC50 = 2.2 nM195
IC50 = 66 nM194
IC50 = 210 - 250 nM194,195
IC50 = 140 nM195
Ki = 10 μM193
Ki = 4.7 nM193
Ki = 20 nM193
Kd = 4.61 pM176
IC50 = 20 nM178
Literature
Affinity
5.4 ± 1.7 nMCGP-54626
20 ± 7.1 nMSKF-97541
208 ± 34 nMBaclofen
139 ± 65 nMGABA
GABA-B
4.1 ± 1.7 μMJG-II-145
264 ± 36 pMOL-135
128 ± 22 pMFAR-I-216
FAAH
129 ± 27 pMCTBGM1
KD
DeterminedLigand
Membrane Bound
Receptor
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Conclusions: 
 The experiments presented in this chapter have shown that it is possible to 
measure ligand – receptor binding events in a solution-based, native membrane 
environment using backscattering interferometry in combination with synthetic and 
reconstituted membrane technology.  This technique helps to maintain the native 
structure of the membrane-associated receptor and has the potential to address many 
applications.  In particular, a high-throughput screening of ligand binding to cell surface 
proteins could serve to simplify the screening of new drug candidates, as well as enable 
the more direct examination of interactions at membrane surfaces.  The chemical control 
imparted by synthetic membranes could very well serve to display ligands that might not 
be amenable to any other environment, as well as enhance the signal-to-noise present in 
such measurements due to factors such as lipid compressibility and consequent dynamic 
rearrangement of water.   
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CHAPTER VI 
 
SMALL MOLECULE RECOGNITION ASSAYS USING 
BACKSCATTERING INTERFEROMETRY 
 
Antibody – Antigen Interactions: 
 
Background and Significance: 
 Billions of different a ntibodies are created in nature by the immune system in 
order to protect the body.196  Antibodies have been used to detect analytes since the 
1950’s197 and by 1975, with the development of the monoclonal antibody,198 antibodies 
began to be produced in large quantities.  Antibodies currently play a large role in 
biological and biochemical research as well as in medicine for both diagnostic and 
therapeutic purposes.199-201  Antibodies are also fundamental to the determination of 
biomarkers that are central to the diagnosis of cancers and other diseases.202-207  As 
antibody production methods have improved,202,208,209 it has become possible to create 
numerous different antibodies faster than it is possible to perform the characterization of 
their binding.199  There are several methods available for antibody characterization, 
however most rely on labeling or on surface immobilization.196,200  As discussed in 
Chapter I, altering a molecule in any way can affect its ability to interact and bind; 
therefore, it is advantageous to have a quick, efficient, free-solution, label-free method to 
measure antibody interactions and to quantify the affinity of the interaction.  BSI has the 
potential to fit this need and the work presented here demonstrates this potential. 
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 Four systems have been chosen to illustrate BSI performance in the 
characterization of antibodies.  These systems include four different small molecules 
(nitrotyrosine, 2,3,6-trinitrophenol (TNP), histamine, and serotonin) and their monoclonal 
antibodies.  Nitrotyrosine is created in the body in the presence of nitric oxide and has 
been linked as a marker for various diseases and inflammatory processes.210-212  TNP is a 
model for explosive materials, which would benefit from a quick detection method.  
Histamine is involved in many systems in the body, including the immune system, the 
gastrointestinal system, and the central nervous system, and works to regulate 
inflammation.213-215  Serotonin is a well-studied neurotransmitter that is also involved in 
the cardiovascular and gastrointestinal systems.216  These molecules were chosen because 
they represent a variety of molecules that are characteristic of antibody targets. 
 
Experimental Procedure: 
 The BSI instrument was set up as previously described using a borosilicate glass 
chip manufactured by Micronit (Chapter III).  Solutions of the antigen alone and the 
antigen – antibody mixture were prepared in Dulbecco’s phosphate buffered saline 
(DPBS) over the concentration ranges outlined in Table 6.1.  The solutions were allowed 
to bind and equilibrate overnight at 4°C.  The antigen solution was introduced into the 
channel and the BSI signal was measured for 15 seconds.  The solution with the same 
concentration of antigen with the antibody present was then introduced into the channel 
and the signal measured.  The channel was then rinsed and the procedure was repeated 
iteratively for increasing antigen concentrations.  The binding signal was calculated as 
the difference in phase between the antigen alone and the antigen – antibody complex 
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(Figure 6.1).  The background signal due to the presence of the antibody was subtracted 
from all concentrations.  The corrected binding signal was then plotted versus 
concentration to form a saturation binding curve and fitted to the square hyperbolic 
function using PrismTM software to calculate the KD value. 
 
Results and Discussions: 
 The interaction between the four small molecules and their antibodies was 
measured and the results are shown in Figure 6.2.  The corrected binding signal 
determined from the phase change in the interferometry signal was found to vary in a 
manner consistent with dose-dependent saturation of a single binding site.  The 
Table 6.1:  Ligand and control molecules studied. 
Ligand Control Concentration Range 
Nitrotyrosine Tyrosine  
  
 
0 – 100 nM 
TNP Phenol  
  
 
0 – 1000 nM 
Histamine Histidine  
 
 
 
0 – 100 nM 
Serotonin Tryptophan  
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dissociation constants calculated (Table 6.2) from these curves were: 1.34 ± 0.21 nM for 
nitrotyrosine (r2 = 0.99), 21.9 ± 4.0 nM for TNP (r2 = 0.97), 330 ± 109 pM for histamine 
(r2 = 0.93), and 10.9 ± 1.4 nM for serotonin (r2 = 0.99).  In all cases, little to no BSI 
response was recorded for the controls, demonstrating the expected specificity of the 
antibody-based detection system.  The controls were molecules with very similar 
structures: tyrosine for the nitrotyrosine antibody; phenol for the TNP antibody; histidine 
A B
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Control + Antibody
Control Signal
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e
Antigen Alone
Antigen + Antibody
Binding Signal
Figure 6.1:  Illustration of the calculation of the (A) control signal and (B) binding signal of the 
antigen – antibody interaction. 
 
 
 
 
Table 6.2:  Summary of the measured affinities of the antibodies studied. 
0.9910.9 ± 1.4 nMSerotonin
0.93330 ± 109 pMHistamine
0.9721.9 ± 4.0 nMTNP
0.991.34 ± 0.21 nMNitrotyrosine
Correlation
(R2)
Affinity
(KD)
Antibody
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for the histamine antibody; and tryphtophan for the serotonin antibody (see Table 6.1).  
For these antibodies, no affinity measurement has previously been performed; however, 
the results are consistent with values typically seen for monoclonal antibodies and are in 
agreement with the recommended concentrations for the antibody for the use in 
immunohistochemistry experiments that detect the presence of the ligand.217,218  Affinity 
measurements are not typically performed for every batch of antibody produced because 
the affinity is not necessary for most qualitative tests and it would require the 
consumption of too much antibody.  This point illustrates the need for a quick, reliable 
method to measure the binding affinity of antibodies that does not use large amounts of 
sample.  BSI required less than 3 µg of antibody for each determination, making it 
perfectly suited to meet this need. 
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Figure 6.2:  Endpoint analysis dose-response curves (red squares) for four small molecule 
antigens and their cognate antibodies: A. nitrotyrosine, B. trinitrophenol, C. histamine, and D. 
serotonin.  Controls (blue triangles) using very similar molecules (A. tyrosine, B. phenol, C. 
histidine, and D. tryptophan) showed no binding and illustrated the specificity of the antibodies. 
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Encapsidated Aptamer Interactions: 
 
Background and Significance: 
 Aptamers are oligonucleotides and are emerging as an alternative for molecular 
recognition assays.  Aptamers were first developed in 1990219,220 and have become 
known for their specificity.221  In fact, aptamers can be developed that are more selective 
than antibodies.222  These molecules are developed and identified in vitro221,223 so they do 
not depend on the animals or cells, which is a significant advantage over antibodies.  This 
development process also creates the advantage of being able to change the properties of 
the aptamer as needed.221  Aptamers can also be synthesized quickly and precisely, 
eliminating batch-to-batch variations.  They are also very stable, so shipments can be at 
ambient temperatures and they can be stored long-term without loss of activity.221  
Because of these advantages, aptamers are quickly gaining widespread acceptance and 
have been used in place of antibodies for numerous applications, including 
chromatography, flow cytometry, electrophoresis, and several biosensors.221,224,225 
 Heteroaryl dihydropyrimidines (HAP, Figure 6.3A) are a class of molecules that 
are not found in nature; therefore, HAP molecules are good targets for aptamer 
development because the dissimilarity in structure should prevent off-target binding to 
other biological molecules.  HAP has also been studied for non-nucleosidic inhibition of 
the hepatitis B virus replication.226-228  Through in vitro selection219,229 an RNA aptamer 
(clone 2-1) to a HAP  was developed by the Finn lab at the Scripps Research Institute.  
The aptamer was then packaged into the coat protein of bacteriophage Qβ, which is 
expressed recombinantly to generate icosahedral virus-like particles (VLPs).  A hairpin 
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RNA sequence is specifically bound by the inside of the capsid and can direct the 
encapsidation of desired RNA molecules.230  The protein capsid is stable to a variety of 
chemical and genetic modifications; therefore, when encapsidated, the aptamer is 
protected from nuclease degradation yet still retains its ability to bind HAP molecules 
that diffuse into the capsid interior.  The Qβ capsid features several large openings in its 
structure142 (Figure 6.3B) which allow small molecules, such as HAP, to easily access the 
interior.   
 
Experimental Procedure: 
 The binding of HAP to four different RNA aptamer sequences packaged inside 
the Qβ capsid was measured in a similar manner as the antigen – antibody interactions.  
These aptamers included the original aptamer (Qβ 2-1), a single point mutant (Qβ A), a 
triple point mutant (Qβ E), and a mutant with the necessary hairpin (Qβ Δhp).  For these 
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Figure 6.3:  A. Structure of the Heteroaryl dihydropyrimidine (HAP) target.  B. Structure of the 
Qβ capsid showing the prominent holes through which HAP can diffuse to the interior to bind the 
encapsidated aptamer.137 
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measurements, the interactions of HAP and a control with an encapsidated nonsense 
RNA strand (Qβ R) was compared to the interactions of HAP and Qβ containing the 
aptamer in a similar manner to the antibody experiments (Figure 6.4).  The solutions were 
made in 50 mM HEPES buffer with 150 mM NaCl and 5 mM MgCl2 and were incubated 
for ~8 hours at 4°C.  The control solution was introduced into the channel and the BSI 
signal was measured for 15 seconds.  The solution with the same concentration of HAP 
with the aptamer present was then introduced into the channel and the signal measured.  
Subsequently, the channel was rinsed and the procedure was repeated iteratively for 
increasing HAP concentrations (10 pM to 15 nM).  The corrected binding signal was 
determined, plotted versus concentration to form a saturation binding curve, and fitted 
with a square hyperbolic function using PrismTM software to calculate the KD value. 
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Figure 6.4:  Illustration of the calculation of the (A) control signal and (B) binding signal of the 
encapsidated aptamer - HAP interaction. 
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Results and Discussions: 
 The interaction between HAP and the four encapsidated RNA aptamers was 
measured and the results are shown in Figure 6.5.  Three of the aptamers were found to 
bind with curves consistent with a dose-dependent saturation of a single binding site.  
The dissociation constants calculated (Table 6.3) from these curves were: 31.4 ± 9.6 pM 
for Qβ 2-1 (r2 = 0.96), 8.96 ± 1.95 pM for Qβ A (r2 = 0.98), and 2.40 ± 0.61 nM for Qβ E 
(r2 = 0.98).  The fourth aptamer mutant, Qβ Δhp, which does not have the necessary 
hairpin to interact, did not show any binding (Figure 6.5D).  For all aptamer mutants, 
little to no BSI response was seen using the control molecule, PEG, illustrating that the 
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Figure 6.5:  Endpoint analysis dose-response curves for heteroaryl dihydropyrimidine (HAP) 
against four mutations of the RNA apatmer packaged inside the Qβ capsid (red squares).  PEG 
was used as a control (blue triangles) and showed little to no binding. 
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binding is specific.  These experiments illustrate the potential of BSI to be used to study 
aptamer binding, in both a traditional application and in an encapsulated manner.  It 
would have been difficult to measure these interactions with another method because the 
affinities of these particles are very high which can make the measurements difficult to 
perform, as described in Chapter II.  Labeling of the HAP would have created a 
considerable change in the ligand structure, giving rise to significantly different RNA 
binding properties.  Additionally, measuring the encapsidated interactions would not have 
been possible using a surface immobilized technique, because the binding partners would 
not be able to get close enough to interact.  The ability to package and protect a molecule 
has uses in vaccine development, cytotoxic drug delivery, and protect RNA sequences 
used to induce protein expression.231-234  A method to characterize these particles in their 
encapsidated form is therefore an important task that BSI is uniquely capable of 
performing. 
 
 
Table 6.3:  Summary of the measured affinities of the aptamers studied. 
non-bindingQβ Δhp
0.982.40 ±0.61 nMQβ E
0.988.96 ± 1.95 pMQβ A
0.9631.4 ± 9.6 pMQβ 2-1
Correlation
(R2)
Affinity
(KD)
Mutant
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Conclusions: 
 It has been shown in this chapter that BSI is capable of quantifying the 
interactions of both antibodies and aptamers, two main types of molecular recognition 
molecules.  Novel measurements of the affinity of four monoclonal antibodies were 
reported and the specificity of the antibodies was demonstrated using very similar 
molecules as controls.  This has demonstrated that BSI is capable of measuring the 
affinities in an efficient, free-solution, label-free manner while only using a minute 
amount of sample.  These unique properties of BSI makes it well suited for use in 
antibody characterization.   
 The affinities of several mutations of an RNA aptamer for HAP were also 
determined.  This is an important system to measure because aptamers are becoming a 
prime area of investigation.  These measurements were performed with the aptamer 
encapsidated inside the coat protein of the Qβ virus-like particle, making this a 
measurement that would have been difficult to impossible to measure with traditional 
methods, such as SPR.  The encapsidation of molecules such as aptamers has shown great 
promise for many uses because of the protection that the capsid provides.  These 
measurements also did not require modification, such as labeling or immobilization, of 
either of the binding partners, further demonstrating the unique abilities of BSI.   
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CHAPTER VII 
 
CONCLUSIONS 
 
 Backscattering interferometry is distinctive and versatile instrument that employs 
a simple optical train to perform highly sensitive, label-free molecular interaction 
measurements.  The unique design of BSI allows for measurements to be performed in 
either a heterogeneous (surface-immobilized) or homogeneous (free-solution) format.   
 Heterogeneous measurements performed in this dissertation (Chapter III) 
measured the relative binding affinities and polyvalent avidities of several glycan – lectin 
pairs.  Because BSI is not a film thickness sensor, these measurements were performed 
with the lectin attached to the surface.  Additionally, an intermediate layer of avidin 
provided spacing between the channel surface and the binding sites in order to create an 
environment more conducive to the maintenance of native structure and function.  This 
study is significant because it demonstrates that BSI uniquely allows quantification of a 
binding event for less than one part in 1000 change in mass.  Another unique aspect of 
BSI demonstrated in these findings is that the BSI response is correlated to the number of 
actual binding events rather than the size of the species that is involved in the binding.  
This is consistent with the theory that the signal is created from conformational changes 
and/or changes in the waters of hydration causing a change in the refractive index.   
 BSI has also shown exceptional sensitivity in the homogeneous format, detecting 
tens of thousands of molecules and monitoring interactions with picomolar affinities, 
without the use of any type of label (Chapter II, V, and VI).  This work has expanded the 
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dynamic range of KD values that BSI is capable of measuring to span six orders of 
magnitude.91  Additionally, BSI has made it possible to measure these interactions in 
complex matrices, such as cell media. 
 The ability of BSI to perform measurements in complex matrices makes it 
possible to use BSI as a reactive serum detector in a clinical setting.  This potential use 
was tested using human serum samples from patients with syphilis (Chapter IV).  A small 
panel of samples was tested using a treponemal antigen and showed sensitivity, 
selectivity, and accuracy when compared with traditional clinical tests.  There was also a 
strong correlation of the BSI signal using nontreponemal antigens with the semi-
quantitative tests currently in practice.  While additional investigations are needed before 
BSI can be used in clinical testing, its potential for the use in performing rapid serological 
tests have been clearly demonstrated. 
 BSI was also applied to the study of membrane-associated proteins, a system that 
is notoriously difficult to study (Chapter V).  Despite the fact that these proteins are the 
target for nearly 70% of drug candidates, current methods to study the interactions 
require some type of modification of one of the binding partners.  Here we were able to 
quantify the interaction of several interactions in a solution-based native membrane 
environment.  The ability to study membrane interactions in this format can provide 
accurate insight into this important class of molecules, and BSI has illustrated that this is 
now possible. 
 BSI has also been used to measure the interaction of several monoclonal 
antibodies and their small molecule ligands (Chapter VI).  The binding affinities for the 
pairs were determined and the specificity of the antibodies was also demonstrated.  In 
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conjunction with these experiments was the measurement of the affinities of several RNA 
aptamer mutants.  The ability of BSI to measure aptamer interactions is important 
because of their growing applications.  Antibody interactions currently play a large role 
in biological and biochemical research and the replacement of antibodies with aptamers 
in these fields is growing. Therefore a method to characterize the interactions between 
aptamers and target molecules quickly and efficiently is needed.  BSI fits this need well, 
demonstrating the ability to accommodate free-solution, label-free binding assays using 
only a small amount of sample.   
 BSI is unique, powerful approach to biosensing and has enabled previously 
impossible molecular interactions studies.  BSI works in free solution and with little a 
priori knowledge of the binding pair, allowing this technique to perform novel binding 
affinity determinations on uncharacterized molecules.  BSI had already been shown to be 
a sensitive technique for quantifying molecular interactions and the work presented here 
extended the limits, showing that low picomolar binding affinities could be measured.  
The range of unique applications that BSI is capable of has also been broadened beyond 
expectations.  The ability to monitor interactions with large particles such as micelles, 
liposomes, and viruses, was once speculation, but has now been proven possible as seen 
in the work reported in this thesis.  Incredibly, it is even possible to quantify binding that 
occurs inside of such a particle.  Further experimentation is needed to fully understand 
the source of the BSI signal with respect to the changes that occur within biomolecules 
during the binding process, though properties such as the dipole moment, waters of 
hydration, and confirmation are likely sources.  BSI has the ability to shift the paradigm 
when attempting to quantify affinity, determine labeling perturbation, or screen for 
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binding.  The process of commercialization of the technology is currently underway and 
will make BSI available to a wide array of researchers.  As the technology continues to 
develop, the potential for BSI, whether used in a laboratory for the development of new 
and better drugs, in a doctor’s office for the diagnosis of diseases, or in the field to study 
environmental contaminants, is extensive. 
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APPENDIX A 
 
PREPARATION OF CARBOHYDRATE COATED VIRAL PARTICLES 
 
Production and Isolation of Virus Particles: 
CPMV particles were produced in cowpea plants and isolated using previously 
published procedures.235  Briefly, CPMV was isolated from infected leaves of black-eye 
cowpea plants.  Primary leaves from 10-day old cowpea plants were first dusted with 
carborundum and inoculated with homogenized infected leaves in phosphate buffer.  
Symptoms of infection appear within a week and a systemic infection is observed after 
three weeks.  Leaves were collected, weighed and frozen for future purification of 
CPMV.  Blended leaf tissue was separated from virus as previously described.235  
Expression of the Qβ coat protein from a recombinant plasmid has been previously 
reported;139 we created our own vector to allow for more convenient genomic 
manipulation, as will be described in detail elsewhere.  A 133-amino acid version of the 
Qβ coat protein gene was cloned into the vector pQE-60 and expressed under IPTG 
control in M15MA cells in SOB media.  After expression, collected cells were lysed by 
sonication and lysozyme treatment and then centrifuged to remove insoluble cell 
components.  Assembled particles were precipitated from the resulting supernatant using 
8% PEG 8000.  Following further centrifugation, the isolated pellet was resuspended in 
0.1M potassium phosphate pH 7.0.  The virus-like particles then underwent a final 
purification by ultracentrifugation through 10-40% sucrose gradients followed by 
ultrapelleting and resuspension in 0.1M potassium phosphate pH 7.0.  
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 Final purification of all viruses was performed by ultracentrifugation through 10-
40% sucrose gradients; we find that this is more reliable than size-exclusion “spin 
columns” previously employed (and still used for preliminary cleanup in some cases).  It 
may be possible to improve upon the maximum recovery of 70-80% from sucrose 
gradients with the use of molecular weight cutoff filtration (resin or membranes), but this 
was not attempted in the studies described here.  CPMV concentrations were determined 
by absorbance at 260 nm (0.1 mg/mL virus sample gives an absorbance of 0.8).  Qβ 
concentrations were determined using the modified Lowry protein assay.236  Unless 
otherwise indicated, all virus samples were handled in 0.1 M potassium phosphate buffer 
(pH 7.0).  
 
Synthesis of Glycan Azides: 
Compounds 3 and 4 were synthesized as previously described from α-mannose 
pentaacetate or β-galactose pentaacetate.237  A solution of pentaacetate (316 mM) and 2 
equiv (633 mM) 2-azidoethanol (CH2Cl2) was placed under dry nitrogen atmosphere, 
cooled to 0°C, and treated with freshly distilled BF3·Et2O (2 equiv) in dropwise fashion.  
The mixture was stirred for 1 hour and the cooling bath was removed to allow stirring 
overnight at room temperature.  The reaction was followed by silica gel thin layer 
chromatography (TLC, 2:3 EtOAc:hexanes), with the product showing Rf=0.4.  The 
mixture was neutralized with solid sodium bicarbonate, filtered, and evaporated.  The 
residue was purified by flash chromatography on silica gel (gradient of 10-50% EtOAc in 
hexanes) to obtain the intermediate pentaacetate azidoethyl adducts in 60-80% yields as 
colorless oils.  EI-MS (M+H+) 417.   
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 Each protected azide-carbohydrate was dissolved in MeOH with 3Å molecular 
sieves under a nitrogen atmosphere.  NaOMe (1% in MeOH, approximately 1 equiv with 
respect to acetate groups) was added dropwise and the reaction was stirred for 45 minutes 
at room temperature, with monitoring by TLC (2:3 EtOAc:hexanes, product Rf = 0.1).  
Dowex 50W x2-200 resin was added to neutralize the reaction, followed by filtration and 
concentration by rotatory evaporation.  The product was purifed by flash chromatography 
on silica gel (9:1 CH2Cl2:MeOH) to obtain pure 3 or 4 in approximately 80% yield as a 
colorless oil.  The NMR spectra of 3 matched the published data.238  The α-anomer of 
azidoethylgalactose has been reported;239 compound 4 is assigned as the β-configuration 
due to its very different anomeric proton chemical shift and coupling constant (4.22 ppm, 
J=10 Hz vs. 4.67 ppm, J=3.3 Hz for the α-anomer).   
 
Derivatization of Virus Particle: 
 Each capsid particle was reacted with a large excess of an NHS ester-alkyne 
reagent to acylate most of the surface lysine side chains (Figure 2.3).  The isolated 
alkyne-derivatized particles were then condensed with azidoethyl derivatives of 
α-mannose or β-galactose150 (3 and 4, respectively) using complex 5 as a precatalyst for 
the copper-catalyzed azide-alkyne cycloaddition (CuAAC) “click” reaction that has been 
developed for the purpose.154,240  This conjugation methodology allows for complete 
coverage of the alkyne groups with modest concentrations of the desired azide under mild 
conditions, irrespective of the other functional groups in the reaction partners.  Particles 
were purified by sucrose-gradient ultracentrifugation.  At each stage (acylation and 
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CuAAC coupling), only intact particles were observed, as characterized by sucrose 
gradient sedimentation and size-exclusion chromatography. 
 The numbers of attached glycans were estimated by performing reactions under 
identical conditions with the selenomethionine azide derivative 6 instead of a glycan-
azide.  Selenium, not present in detectable levels as background, can be quantified at sub-
µM concentrations using inductively coupled plasma optical emission spectroscopy (ICP-
OES).  Along with the independent determination of protein concentration in each 
purified sample by a modified Lowry assay, this provides a measurement of the average 
number of attachments made per virion by the CuAAC reaction.  An experimental error 
of 10% is typical for independent reactions under identical conditions.  Compound 6 is 
designed to replace dyes such as fluorescein that we have previously used to determine 
loading on capsid scaffolds,143,152 since 6 more closely resembles the hydrophilic 
character of carbohydrates and thereby provides a closer analogy to their attachment.  
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APPENDIX B 
 
PREPARATION OF MEMBRANE VEXICLES 
 
Synthetic Membranes: 
 A lipid solution containing 1,2-Dimyristoleoyl-sn-glycero-3-phosphocholine 
(DMOPC) and 1,2-dimyristoyl-sn-glycero-3-[phospho-L-serine] (sodium salt) (DMPS) in 
chloroform was evaporated onto small round-bottom flasks and hydrated for an hour at 
4ºC in PBS to ~3.3 mg/mL.  The lipids were probe-sonicated to clarity in an ice-water 
bath and transferred to a 100nm Millipore Ultrafree-MC centrifuge tube filter.  Samples 
were centrifuged for 2 hr at 16,000 g and 4ºC.  All solution that passed through the 
centrifuge tube filter was collected and stored at 4ºC for up to one week.  Full-length 
FAAH was incorporated into synthetic lipid vesicles by mixing together FAAH and 
SUVs to a final concentration of 100 µg of protein per 1 ml of centrifuged SUV solution.  
The resulting mixture was then dialyzed extensively against PBS to facilitate complete 
removal of detergent and form proteoliposomes.  Proteoliposomes were stored at 4ºC for 
up to one week.  
 
Mammalian Cell Cultures: 
 Two different lines of adherent Chinese hamster ovary (CHO-K1) cells were 
used; one wild-type, and one engineered to express the full length transmembrane 
GABA-B.  Cells were grown at 37ºC and 5% ambient CO2 to near 100% confluence over 
three days from initial addition to 175 cm2-area flasks.  Cells were harvested by removing 
94 
all growth medium from the flask and incubating with 4ml of Detachin solution for 5 min 
at 37ºC.  48 mL of incubation buffer was then added to the flask and the contents 
removed and transferred to two 50ml centrifuge tubes.  The cells and media were 
centrifuged for 5 min at 300g to pellet the cells.  Following centrifugation, the media was 
removed from the centrifuge tubes, the cells were re-suspended in PBS, and the cell/PBS 
suspension was re-centrifuged.  Cell pellets were rinsed three times in PBS and used 
immediately.   
 
Native Membrane Vesicles: 
 A cell pellet containing approximately 1x109 cells (of either type) was 
re-suspended in 20 mL of ice-cold lysis buffer (2.5 mM NaCl, 1 mM Tris, 1x EDTA-free, 
broad-spectrum protease inhibitors, pH 8.0) and placed on a rotator for 45 minutes at 4ºC.  
The resulting solution was then centrifuged at 40,000g for 60 min at 4ºC.  The 
supernatant was removed and re-suspended in 4 mL of ice-cold PBS and transferred to a 
5 mL glass dram vial.  The pellet and buffer were then probe-sonicated to clarity in an ice 
bath and transferred to a 220nm Millipore Ultrafree-MC centrifuge tube filter.  The 
resulting solutions were centrifuged for 1 h at 16,000 g and 4ºC.  All solution that passed 
through the centrifuge tube filter was collected and stored at 4ºC for up to two days. 
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